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ABSTRACT 
 
Knowledge of population vulnerabilities to infectious diseases is key in managing many public 
health problems and for mapping appropriate strategies for prevention or intervention. A 
number of genes associated with resistance to HIV infection, such as the double deletion of 32 
base pairs in the CCR5 gene , have been described and potentially account for lower HIV 
infections in some populations. The magnitude of the HIV pandemic in Sub-Saharan Africa 
warrants an investigation of the peculiar genetic factors that may have exacerbated its spread. 
An understanding of the genetic factors that are involved may aid in the development of 
specific strategies for prevention such as vaccine development, genetic counselling as well as 
gene therapy. The aim of this project was therefore to study the relationship between blood 
groups and HIV-infection in Botswana. HIV infection in Africa has not been linked to 
particular blood groups. 
The project was undertaken in two phases from December 2012 to December 2017. In the first 
phase, 346 subjects of known HIV status (negative or positive) were phenotyped for 23 
erythrocyte antigens via standard scientific procedures. A Chi-square analysis was used to 
determine those antigens associated with increased or reduced risk of HIV infection. In the 
second phase, 120 samples were phenotyped for the protective blood group (RhC) and the risk-
associated groups (Lub and P1). The samples were also characterized according to their 
laboratory results for viral load, lymphocyte sub-populations, complete blood count and blood 
chemistry, including total cholesterol. Some of the samples were also assessed for erythrocyte-
associated viral RNA. 
Generally, the prevalence of the blood groups in the general population in Botswana did not 
differ with the known prevalence for Africans broadly. Three novel findings were established. 
First, the blood group Rh(C) was associated with a 40% risk reduction for HIV infection. 
Immunologically, carriage of the C antigen was associated with a more robust cell-mediated 
immunity as evidenced by enhanced cytotoxic T cell counts. Moreover, this antigen occurred 
with a frequency lower than 30% in all countries where HIV prevalence was high. There was 
therefore an inverse relationship between Rh(C) frequency and HIV prevalence. An 
examination of reports from previous studies revealed that the pattern was consistent in Africa, 
Europe, Asia, South America and Caribbean countries. It appears that the population frequency 
of this antigen explains, at least in part, a genetic factor that puts some African populations at 
higher risk for HIV infection. These results are novel in that Rh antigens have not been 
previously associated with immunity in any reports.  
Novel findings regarding the P1 blood group was its association with a double risk for HIV 
infection. While the plasma viral load did not differ between P1-positive and P1-negative 
subjects, P1-positive erythrocyte lysate yielded more viral RNA than P1-negative cells, 
implying more intracellular HIV RNA. Intra-erythrocytic viral RNA was detected even in 
patients with an undetectable plasma viral load. Glycosphingolipids, of which P1 is an example, 
have been documented to promote viral fusion to cells independent of CD4 receptors or other 
ligands. In at least one report, the presence of sphingolipids in lipid rafts was considered to be 
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sufficient for viral fusion. The presence of viral RNA even in erythrocyte lysates corroborates 
this phenomenon and potentially explains the double risk of HIV infection observed. The 
occurrence of HIV RNA in erythrocyte lysate is a novel finding that suggests a new viral 
reservoir. Apparently, P1 has a high frequency among Africans and low in other races. 
The Lub blood group was associated with triple risk for HIV infection and a lower absolute 
count of circulating monocytes. This monocytopenia was accentuated in the presence of higher 
cholesterol levels and in the presence of the Lub antigen. The occurrence of monocyte depletion 
in a setting of high cholesterol plus an adhesion molecule suggests conditions that favour 
atherosclerotic plagues. The increased risk of HIV-infection in Lub positive individuals is 
therefore likely linked to tethering and emigration into tissues, thus disseminating the virus to 
distant organs.  
Our results suggest that blood group C protects against HIV infection by enhancing cytotoxic 
T-cell counts. Furthermore, the P1 blood group potentially promotes HIV infection by creating 
viral reservoirs within the erythrocytes that can later be released when aging erythrocytes are 
trapped in the spleen and engulfed by splenic macrophages. The Lutheran blood group appears 
to enhance monocyte depletion in a setting of hypercholesterolemia and chronic inflammation 
created by HIV infection. So, while it is generally accepted that cardiovascular disease has a 
genetic predisposition, the results of the current study suggest that Lutheran blood group 
antigens may be a novel part of that genetic milieu of atherogenic factors in HIV-positive 
persons. The results further suggest the prophylactic possibility of suppressing endothelial 
expression of Lutheran antigens or modulating the expression of integrins on monocytic cells 
to reduce the adhesion risk. Finally, the ability of HIV to fuse to glycosphingolipids 
independent of CD4 receptors raises the possibility that HIV virions could be targeted by use 
of RNase-laden glycosphingolipid liposomes in post-exposure prophylaxis or where there is 
need to rapidly reduce the plasma viral load. 
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PREFACE 
 
This dissertation is presented in article format. The chapters appear in the format of the journals 
in which they have been published or submitted for publication.  
Chapter 1 is the general Introduction, which basically puts the problem in perspective. Here 
the attention of the reader is drawn to the magnitude of the HIV and AIDS problem globally as 
well as in Botswana, which is the particular setting of the current research project.  
Epidemiologic data from UNAIDS on both the global and local situations is presented to 
underscore the importance of the subject. The role of erythrocyte antigens as binding sites for 
infectious agents is discussed with examples of other infectious agents that specifically bind to 
blood group antigens. The chapter then makes a brief reference to the role of red blood cells 
(erythrocytes) in HIV-infection and singles out red cell antigens as potential binding entities in 
the transmission of HIV to susceptible cells, thus justifying the relevance of the blood groups 
in HIV research. 
 Chapter 2 is a more detailed review of literature on the role of the erythrocytes in HIV and 
other diseases. A review article from this thesis was published in BioMed Research 
International journal in 2013. The paper points to the fact that frequencies of blood groups 
differ among populations partly due to breeding practices as well as disease-induced selection 
pressure. Individuals whose cell antigens provide binding sites for pathogenic microorganisms 
will naturally be susceptible to negative selection. The paper further discusses a number of 
erythrocyte antigens that have been linked to diseases, prototype of which is the Duffy antigen 
that has been eliminated to a significant level in individuals living in endemic malaria areas. 
Controversies in this area of research are also addressed.  
The physiologic function of erythrocyte antigens is discussed to highlight relevance to normal 
function in general, and to innate immune responses. A detailed discussion of the role of blood 
groups in specific diseases, including potential mechanisms of cytopathic effects in HIV-
infection concludes the paper.  
Chapter 3 (This part of the research work has been published as an article in the journal: PLOS 
One). The paper reports the screening of 346 HIV-infected and uninfected controls for 23 
antigens, these being A, B, “O”, D, C, c, E, e, Fya, Fyb, Jka, Jkb, Kpa, Kpb, Lea, Leb, Lua, Lub, 
M,N, P1, S, and s. In this study, one blood group, Rh(C), also designated as rh’ or Rh2, was 
found to be protective while two blood groups, P1 and Lu
b, were associated with significantly 
increased risk for HIV-infection. Our data also contributed to the hotly contested role of the 
Duffy blood group as risk factor for HIV infection as none was found in our study. The rest of 
the blood groups investigated were not associated with significant risk or protection. Another 
important finding of this investigation was that the protective blood group Rh(C) occurred 
much less frequently among Africans than it did among Caucasians and Northern Indians while 
the risky blood groups, P1 and Lu
b had prevalence in excess of 90%. Information available in 
the literature was helpful in relating the biochemical nature of the risky blood groups to the 
study observations. However, the protective mechanism for Rh(C) appeared inexplicable in the 
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absence of information on the biological role of this antigen.  Mechanisms were therefore 
suggested for the risk-association of these antigens. 
 Chapter 4 is an article that is under review by the African Journal for Laboratory Medicine.  
The substance of this article sought to gain insight into the mechanisms accounting for the risk 
observed in the Lutheran blood group. The Lutheran blood group antigens are members of the 
immunoglobulin superfamily and act as adhesion molecules expressed on monocytes and 
endothelial cells. Carriage of the Lub antigen (also designated LU2) was associated with a lower 
monocyte count, and the count diminished with increasing cholesterol levels. This cholesterol-
associated monocyte depletion was accentuated in Lub-positive individuals but virtually absent 
in Lub-negative subjects.  The depletion of monocytes in a setting of high cholesterol and 
chronic inflammation points to an atherogenic environment and potentially explains why HIV-
infected individuals are prone to cardiovascular disease. Moreover, if this depletion truly 
represents extravasation of monocytes, this could explain the increased risk of infection as 
infected monocytes migrate and introduce the virus to other anatomical sites. Novel findings 
here include both the increased risk of infection in LU2 individuals as well as the monocyte-
depleting effect of this blood group. 
Chapter 5 presents the findings as they relate to blood group C (or Rh2). The main finding here 
was the association of Rh2 expression with both a lowered risk for HIV-infection in the context 
of enhanced cytotoxic T-cells counts. These cells are important for the control of viraemia and 
are known to confer resistance in long term progressors and non-progressors. This is the first 
report linking an antigen in the Rh system with immune function.  
Chapter 6 reports on the findings relating to the P1 blood group. Since P1 is a glycosphingolipid 
capable of promoting viral fusion with cell membranes, evidence for intra-erythrocytic viral 
RNA was sought. The study confirmed the presence of erythrocyte-associated HIV RNA in 
patients with or without detectable plasma viral load. However, this viral pool was not 
detectable in every patient with a detectable or even high viral load. P1 blood group was 
associated with increased intra-erythrocytic HIV-1 RNA. This too was consistent with the role 
of this blood group, a glycosphingolipid, which enhances the fusion of the virus to cells, thus 
promoting infection.  
Based on these studies, it can be concluded that there is adequate scientific evidence for the 
role of blood groups C, P1 and Lu
b in enhancing or preventing HIV-infection, thus the purpose 
of this study was achieved.  
Chapter 7 presents a general discussion and conclusions. Here all the main novelties are 
highlighted with potential mechanisms. The prevalence data is compared with HIV prevalence 
in various countries to show that the findings in this study are consistent with severity of the 
disease in those countries or communities. Uganda and Botswana stand out in that respect.  
Chapter   8 provides recommendations for further enquiries to elucidate specific research 
questions emanating from this study.
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CHAPTER ONE 
INTRODUCTION 
 
The HIV Pandemic in Botswana 
 
The HIV and AIDS pandemic is one of the world’s worst health-related catastrophes in recent 
history. UNAIDS estimates that since its start in the early 1980’s, the pandemic has infected 
more than 70 million people and claimed at least half the lives of those infected as at the end 
of 2016 (UNAIDS, 2017a). It is further estimated that 36.7 million people are living with the 
virus world-wide, with 1.8 million new infections experienced in 2016.  The report further 
takes cognizance of the notable variation between countries and regions, but Sub-Saharan 
Africa is the most severely affected region and bearing 2/3 of global infections (UNAIDS, 
2017a).  
On the economic front, the virus has prompted the commitment of massive resources for 
prevention and treatment programmes, with US$19.1 billion  having been committed to support 
low and middle income countries in 2016 alone (UNAIDS, 2017a). 
 Botswana is one of the worst-affected countries by the HIV pandemic. During the period 1992 
to 1994, the country experienced a dramatic increase in the HIV prevalence with urban areas 
such as Gaborone and Francistown jumping from 15% to 28% and from 23% to 30% 
(Macdonald, 1996), respectively.   
In 2002, the Government of Botswana introduced the Masa Project, in which anti-retroviral 
treatment was offered to eligible individuals (Farahani et al., 2014). Initially, the criterion for 
initiation of combination anti-retroviral treatment (cART) included a cut-off CD4 cell count 
(initially 200 cells/µL). This programme radically reduced mortality rates from 63% in 2002 
to 0.8% in 2010 (Farahani et al., 2014). In 2004, the government of Botswana scaled up the 
anti-retroviral (ARV) programme and began to offer HIV-testing at health service points as 
well as voluntary testing and counselling centres around the country. The clinical efforts were 
also accompanied by intense clinical trials and other forms of research that developed robust 
interventions such as the Prevention of mother-to-child (PMTCT) study (Shapiro et al., 2013) 
and the micronutrient studies that added to the quality of the clinical interventions. Based on 
continuous research, strategies were modified to obtain best practices (Zash et al., 2016). 
Through sustained and focused clinical and laboratory-based studies (Novitsky et al., 2010), 
the Botswana Programme ultimately graduated to a “Treatment as Prevention” or “Treat-all” 
programme (Botswana Ministry of Health, 2016)  based on the observation that individuals 
who achieved viral suppression were less likely to transmit the virus to their partners(Hayes et 
al., 2011). 
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In 2010, the country was reported to be the world’s second worst hit country with prevalence 
rates then at 17.6% and as high as 20% in women (Kandala et al., 2012). The current UNAIDS 
reports indicate that at least 350,000 individuals in Botswana are living with the virus in a 
population barely exceeding 2 million, with a prevalence of 22.2% in the age group 15-49 years 
of age (UNAIDS, 2017b).  This astounding spread of the virus may have been due to peculiar 
genetics of the population in addition to other socio-economic factors. 
Statement of the Problem 
Population genetics is an important consideration in studying the epidemiology of infectious 
diseases. Blood groups are genetically-determined antigens carried on red blood cells or 
erythrocytes that are inherited as co-dominant Mendelian traits. Blood groups are mainly 
important in blood transfusion because they determine compatibility of donor and recipient 
cells. However, some blood group antigens function as receptors for infectious agents such as 
malaria (Hadley and Peiper, 1997), parvo virus (Brown et al., 1993) and Helicobacter pylori 
(Anstee, 2010, Aspholm-Hurtig et al., 2004). In recent years, the binding of the human 
immunodeficiency virus to erythrocytes and the apparent increased infectivity of such bound 
virus has sparked interest in this potential viral reservoir  (Puri et al., 1998, Hammache et al., 
1999, Beck and Alving, 2011). Blood groups therefore emerge as logical binding sites for the 
virus on erythrocytes and candidate molecules for scientific enquiry.  
The aim of this research project was therefore to identify blood group antigens associated with 
increased or decreased HIV infection and, where possible, elucidate the underlying 
mechanisms. The results of the study were intended to help clarify the genetic basis of the HIV 
epidemic as it relates to blood groups in the Botswana population. The discovery of HIV-
resistant blood groups could open a number of frontiers for prevention and treatment of HIV. 
Couples seeking artificial fertilization may have the option of semen of the appropriate blood 
group to produce HIV-resistant offspring. Furthermore, research efforts could be focussed on 
the use of hematopoietic stem cells as these are better tolerated in the developing foetus. 
Consideration could also be made for using blood transfusion to treat infections or as pre- or 
post-exposure prophylaxis.  
 
The Aim of the Study 
The overarching aim of this study is to identify candidate antigens that may predispose to or 
impact on the risk for HIV infection, and if any are identified, to investigate potential 
mechanisms by which protection or risk is conferred.  
Specific objectives 
The objectives of the study were: 
a. Estimate the population frequencies of 23 blood group antigens in Botswana. 
b. Compare the occurrence of blood groups in HIV-infected versus uninfected 
individuals. 
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c. Investigate the mechanism responsible for increased or reduced susceptibility to 
HIV infection. 
Hypothesis:  
Ho: Blood groups are not associated with HIV infection.   
Ha: Some blood groups are associated with HIV infection. 
 
In the light of the above, the research sought to answer the following questions: 
1. What are the frequencies of the 23 blood group antigens in the Botswana 
population? 
2. Is there any difference in occurrence of HIV among the different blood groups? 
3. What mechanisms account for the difference in susceptibility to HIV infection 
among the blood groups? 
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Summary: 
AIM: To highlight the apparently neglected role of red blood cell antigens in the epidemiology 
of infectious diseases, with particular focus on HIV, with the prime objective of stimulating 
research in this area. 
METHOD: PubMed database was searched for relevant articles from 1984 to 2013, this being 
the era covering active HIV research. However, the review was limited by the relative scarcity 
of articles on the subject, and only articles written in English were reviewed. 
RESULTS: Substantial documentary evidence attests to the ability of infectious agents to bind 
to erythrocyte-borne molecules, thereby facilitating infection. 
CONCLUSION: Mature erythrocytes, by their lack of a nucleus are not candidates for HIV 
infection. Emerging information, however, suggests that red blood cell antigens may be 
important in the pathogenesis of many diseases, including HIV as they bind free viruses and 
viral immune complexes and are instrumental in transmitting the virus to susceptible cells. The 
role of erythrocyte surface molecules acting as viral binding sites is discussed in light of current 
scientific knowledge. 
Key Words: Blood groups, HIV infection, Erythrocyte-bound HIV, chemokines, disease 
associations 
 
Introduction  
Blood groups have been known to exist for centuries ever since man entertained the possibility 
of replacing blood loss through transfusion. They are responsible for determining compatibility 
of blood in transfusion medicine and are also responsible for foetal loss in haemolytic disease 
affecting the foetus or new born (Bowman, 1996).   
Blood groups are inherited as Mendelian co-dominant(Neil et al., 2003) traits and should be 
expected to occur in somewhat comparable frequencies in the human race. However, 
differences do exist in the distribution of blood groups in various human populations. This has 
been largely attributed to selection pressure as endemic diseases appear to have a predilection 
for selected blood groups leading to the demise of individuals bearing those susceptible blood 
group antigens(Anstee, 2010, Le Pendu et al., 2006). But certainly, there must be more to blood 
groups than just causing problems in blood transfusion and predisposing to myriad self-
annihilation prospects.  
On the other hand, HIV has emerged as one of the major public health concerns of the 21st 
century. Some genetic factors have been cited as contributors to HIV susceptibility or 
resistance, among them blood groups such as ABO/Rh(Sayal et al., 1996, Arendrup et al., 1991, 
Abdulazeez et al., 2008, John et al., 2011, Neil et al., 2003), Duffy(Bolton and Garry, 2011, 
Lachgar et al., 1998, Ramsuran et al., 2011, He et al., 2008) and Pk(Lund et al., 2009).  
However,  the matter has not been without controversy as some investigators have reported 
findings to the contrary(Ukaejiofo and Nubila, 2006, Winkler et al., 2009) against what appears 
to be conclusive evidence of red cell interaction with the virus(Bolton and Garry, 2011, Beck 
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et al., 2009, Puri et al., 1998, Hammache et al., 1999). Blood groups therefore appear to have 
a contribution to public health, at least in the area of infectious disease, which makes it 
imperative to synthesize available knowledge in an attempt to decipher the extent to which red 
blood cell (RBC) antigens are involved in HIV epidemiology and to unveil avenues for future 
research; here follows a synthesis of current research on the beneficial and detrimental effects 
of RBC antigens with probable molecular explanations. 
Methods: 
A literature search was performed on the PubMed database. This was achieved by using the 
phrases ”erythrocyte blood groups AND HIV” (81 articles) or “red cell antigen, blood groups 
AND HIV” (60 articles). A manual search was also done using Google Scholar and 
supplemented by other original articles referenced by various authors. 
Physiologic Functions of RBC Antigens 
The physiologic functions of most blood group antigens are unknown (Greenwell, 1997). Few 
antigens, however, such as the Kidd (urea transporter), Diego (anion exchanger), Colton (water 
channel), Cromer (Decay Accelerating Factor) and Duffy (chemokine receptor) have had their 
physiologic functions somewhat elucidated (Mudad and Telen, 1996, Telen, 1995). The 
importance of such functions remains a matter of debate though, since individuals who are 
negative for these blood group antigens live an apparently normal life (Daniels, 1999).  
A lot has been documented about the Duffy blood group as a chemokine receptor, a function 
that has led to its designation as the Duffy antigen receptor for chemokines (DARC), and to 
the investigation of its potential role in modulating the inflammatory response (Hadley and 
Peiper, 1997, Lachgar et al., 1998, Nibbs et al., 2003, Gardner et al., 2004, Bolton and Garry, 
2011). Chemokines are important for recruiting white blood cells to the site of infection or 
inflammation by binding to their receptors. However, HIV also uses these chemokine receptors 
as co-receptors for its entry into permissive cells. It is known that R5 viruses utilize CCR5 
while R4 viruses use CXCR4 as a co-receptor. The binding of HIV to the co-receptor and its 
subsequent entry into the cell is inhibited by chemokines which act as competitors for the 
binding site (Lachgar et al., 1998, Bolton and Garry, 2011).  The Duffy antigen receptor for 
chemokines binds a wide range of chemokines and thus competes with white blood cells for 
chemo-attractants as well as increase cell exposure to HIV infection. DARC also binds other 
inflammatory mediators such as interleukin 8 (IL-8), RANTES and monocyte chemo-attractant 
protein-1 (MCP-1) (Telen et al., 1990, Reich et al., 2009, Cartron, 2010), all of which are 
important in contributing to a successful  defence against pathogens. 
Red blood cells also bear the CD44 antigen, a ligand for hyaluronic acid. Binding of hyaluronic 
acid to this RBC antigen would have the significance of dampening its inflammatory effect.  
As in the case of the Duffy antigen binding to chemokines, this erythrocytic property may be 
important in absorbing excess stimulant signals intended for inflammatory cells, thereby 
modulating immune responses (Telen, 1995). In cases where the stimulant is produced in small 
amounts, it is plausible that erythrocyte antigens, by their sheer numbers, may out-compete the 
intended cells, leading to an immunological hypo-response. 
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Human red blood cells not only transport oxygen and carbon dioxide, but are important in the 
elimination of many molecules from circulation, including products of immunologic reactions. 
RBCs possess adhesion molecules that bind complement fragments(Horakova et al., 2004) and 
are therefore important for capturing and delivering such complexes to the reticulo-endothelial 
system for elimination from circulation. In this regard, Horakova et al(Horakova et al., 2004) 
investigated the binding of HIV immune complexes to erythrocytes. Their investigations led to 
the conclusion that at least three mechanisms are involved, these being; the binding of 
complement-opsonized immune complexes via CR1, direct binding of the virus in a 
complement-dependent manner but in which specific antibodies were not required, and a third 
mode in which complement was not required at all. Their conclusion was that the third mode 
of binding might be instrumental in the spread of infection at the time of primary infection 
when specific antibodies would not have been formed yet. 
Some RBC antigens are also known to bind inflammatory mediators with potential to affect 
innate immune responses (Telen, 1995, Hadley and Peiper, 1997). These RBC antigens absorb 
and limit the amount of chemokine stimulant activity (Reich et al., 2009). Indeed it has been 
demonstrated that mice lacking the Duffy antigens exhibit a greater inflammatory response to 
CXC and CC chemokines compared to homozygotes or heterozygotes (Dawson et al., 2000). 
This is consistent with the role of Duffy as a “chemokine sink” created by chemokine-binding 
sites on DARC(+) erythrocytes. But, paradoxically, the absence of the Duffy antigens has also 
been associated with a low neutrophil count (Reich et al., 2009, Ramsuran et al., 2011). Given 
the observation that DARC also binds HIV and is capable of transfecting CD4 cells (Lachgar 
et al., 1998), it is probable that HIV-binding to erythrocytes represents an action of various 
molecules acting in synergy.  
 
Blood Group Disease Associations 
On the pathological front, however, certain blood groups have been associated with diseases. 
Individuals of blood group A, for example, are known to be more susceptible to coronary heart 
disease (CHD) independent of known risk factors than other ABO blood groups (Wazirali, 
2005). This is further corroborated by the observation that group A individuals also have higher 
levels of low density lipoprotein (LDL) cholesterol (Greenwell, 1997). Although the molecular 
aspects of this observation still remains to be elucidated, the observation implies that this 
antigen has potential to either influence synthesis of, or inhibit the natural metabolism of these 
lipids, thus predisposing individuals to CHD. The same study, on the other hand, reported a 
lower risk for this condition among group O individuals. 
Additionally, blood group A and B are known to be highly susceptible to thrombotic disorders 
in contrast to group O individuals who are more at risk for bleeding than thrombotic 
events(Clark and Wu, 2011, Schleef et al., 2005, Lourenço et al., 1996). This observation has 
been attributed to higher levels of Factor VIII and von Willebrand factor in A and B individuals 
while the levels may be as low as 30% in group O individuals. Blood groups A and B antigens 
have been demonstrated on these coagulation molecules and are thought to prolong their half-
life, leading to higher concentration in non-O individuals (Jenkins, 2006). 
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Blood Group A has also been associated with malignancies such as cancer of the ovary, cervix, 
rectum, breast, stomach and leukemia (Greenwell, 1997). This is thought to be due to an 
abundance of high-affinity binding sites for epidermal growth factor (EGF) on blood group A 
red blood cells compared to blood groups O and B (Engelmann et al., 1992). Since blood groups 
may be expressed on tissues other than red cells(Telen, 1995), it is plausible that the binding 
of EGF to these binding sites may indeed promote cancer development. Conversely, some 
malignancies have been observed to positively or negatively modulate blood group antigen 
expression to varying degrees depending on the anatomical site (Greenwell, 1997). Thus, 
gastric carcinomas were found to be associated with increased expression of ABH and Lea 
antigens while colonic cancers were associated with expression of Leb and low expression of 
the other antigens. In other studies, enhanced fucosyltransferase activity was reported in 
endometrial cancer leading to unexpected expression of Lea, Leb and H antigens (Ravn, 1992, 
Ravn et al., 1994).  
The Duffy blood group is probably one of the most studied blood groups in relation to disease 
association. Individuals who are homozygotes or heterozygotes for the Duffy antigens, Fya or 
Fyb, are vulnerable to malaria parasites Plasmodium vivax and Plasmodium knowlesi. 
Individuals that lack both Duffy antigens, Fy(a-b-) and therefore lack the receptor for malaria 
parasites are constitutively resistant to these forms of malaria (Barnwell et al., 1989, Telen, 
1995).  
Blood Groups in HIV and other viral Infections 
Blood Groups in HIV Infection 
Most research on HIV has focused on cells of the immune system to the exclusion of viral 
interactions with red blood cells. However, emerging evidence, suggests that red blood cells 
may be important in the pathogenesis of HIV as they enhance viral infectivity by binding free 
viruses (Beck et al., 2009) as well as viral immune complexes (Hess et al., 2002, Horakova et 
al., 2004, Beck et al., 2009), and through such binding transfect HIV-susceptible cells (Hess et 
al., 2002, Horakova et al., 2004).  
HIV infection has been reported to occur in select blood groups in some regions of the world. 
A study by Sayal et al.  in India reported a preponderance for infection in group O Rh(D)-
positive men and least among Group B positive and D-negative ones. However, a close 
examination of the results reveals insufficient statistical analysis rendering the differences 
statistically insignificant. Similar studies by Nneli et al  (Nneli et al., 2004) and John et al (John 
et al., 2011) suffered similar deficiencies. In these studies, group O positive individuals were 
thought to be highly susceptible, but again the studies lacked the statistical rigor to indicate the 
level of significance and have been contradicted by other investigators (Ukaejiofo and Nubila, 
2006). A statistical interrogation of the data in each of the above case does not support the 
conclusion of statistical significance. 
It would then appear that current scientific information does not support a potential role for 
ABO blood groups in HIV infection. In fact, evidence from other studies would suggest the 
contrary for group O individuals. Since HIV virions have been shown to acquire the blood 
group antigens of the infected individuals(Rachkewich et al., 1978, Neil et al., 2003, Arendrup 
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et al., 1991), such virions would be neutralized by naturally-occurring antibodies in group O 
individuals, thus offering protection in blood group-discordant couples (Neil et al., 2003). It is 
noted, however, that this protection will not be available if the source of infection was of a 
similar blood group. Moreover, given the apparently uniform risk of infection among ABO 
blood groups, it is doubtful if this neutralization is of any clinical consequence, especially with 
reference to HIV-1 infection. It remains to be demonstrated then whether HIV from blood 
group A or B is able to infect group O CD4 cells. 
In a separate study, Abdulazeez  and colleagues (Abdulazeez et al., 2008) working with HIV-
1 and 2 reported a higher prevalence of HIV-2 (71.4%) compared to HIV-1 (7.1%) in the AB 
blood group and that Rh(D) positive (97.8%) was more susceptible than D negative (2.2%). 
However, these findings are yet to be confirmed by other investigators. 
The lack of direct empirical evidence for ABO blood groups does not, however, obliterate the 
possibility of associations in other blood groups. Since secreted blood group substances can be 
adsorbed onto lymphocyte membranes (Rachkewich et al., 1978, Arendrup et al., 1991, Neil et 
al., 2003), the presence of these antigens could potentially alter cell behavior. Blood group 
antigens, being glycoproteins and glycolipids, are highly charged molecules that are bound to 
affect their molecular micro-environment, including protein conformation and receptor/CD4 
localization and function (Greenwell, 1997, Lund et al., 2009). Glycosphingolipids and 
glycoproteins have in fact been demonstrated to facilitate fusion of HIV-1 with CD4 cells by 
independent investigators, thus acting as alternative co-receptors for the virus (Puri et al., 1998, 
Hammache et al., 1999). There exists a theoretical possibility therefore, that membrane-bound 
blood group substances on CD4-positive cells may thus affect the affinity of viral-binding 
proteins and viral infectivity, promoting or diminishing cell susceptibility to infection. 
Apparently, both the promotive and inhibitory effects of blood groups in HIV infection have 
been documented. The Duffy antigen receptor for chemokines (DARC) has been reported as a 
binding site for HIV-1 on red blood cells, which binding increases infectivity for permissive 
cells(Lachgar et al., 1998, He et al., 2008). Although some investigators have refuted the role 
of this antigen in HIV-1 infection(Winkler et al., 2009, Horne et al., 2009), the preponderance 
of evidence is heavily in favor of this role, including recent findings of sequence similarities 
between HIV-1 V3 loop and the Plasmodium vivax Duffy-binding protein, both of which bind 
to DARC.  
Furthermore, the Duffy Null phenotype has been associated with increased susceptibility to 
HIV infection among African Americans, elevating the odds of acquiring HIV by as much as 
40%, while those negative for the antigen were observed to exhibit slower progression to AIDS 
(He, 2008). Although these findings were later refuted by other investigators (Winkler, 2009, 
Horne et al., 2009), there is persuasive evidence suggesting the role of DARC in binding the 
virus and facilitating transfection of permissive cells(Ramsuran et al., 2011, Lachgar et al., 
1998, Bolton and Garry, 2011). These reports were given further credibility by findings that 
the Duffy-binding protein of Plasmodium vivax bore sequence similarity with the V3 loop of 
HIV1(Bolton and Garry, 2011). 
He et al (He et al., 2008) reported that the DARC+ phenotype was associated not only with 
higher rates of HIV-1 infection, but also that DARC+ red cells transfected HIV-susceptible 
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cells with X4 variants more efficiently than it did with X5 variants. Blocking of the DARC 
with monoclonal antibodies or other natural ligands significantly reduced viral binding, thus 
confirming the role of DARC in the interaction. However, the blocking of the DARC did not 
totally obliterate HIV binding to erythrocytes, thus suggesting possibilities of involvement of 
other binding molecules as hypothesized by Beck et al(Beck et al., 2009). Similar findings were 
also reported from a study involving commercial sex workers in South Africa, where 
investigators found that a Duffy-null phenotype with low neutrophil counts was predictive of 
HIV-1 sero-conversion (Ramsuran et al., 2011). 
Another such molecule is the Pk RBC antigen, which has been reported to confer resistance to 
HIV infection in lymphocytes in vivo and in vitro. In this Canadian study, the level of 
expression of Pk antigen on peripheral mononuclear cells (PBMC) was positively correlated 
with anti-viral protection (Lund et al., 2009).  The Pk antigen has a low frequency (one in a 
million)(Lund et al., 2009) among Caucasians and is thought to have contributed to reduction 
of HIV spread among such populations. The CCR5∆32/∆32 is another mutation that is 
prevalent in the same population at 1-3% (He et al., 2008) and is known to confer resistance to 
HIV infection. While it has been argued that the lack of Pk among Africans may not account 
for the difference in the epidemiology of HIV in sub-Saharan Africa (given its low frequency 
among Caucasians), one could nevertheless consider the combined effect of both genes in the 
same population and the number of contacts that could have been generated if such genes were 
not operational, compared to a population that lacks both. 
In addition, Beck et al demonstrated that human red blood cells bind HIV virions independent 
of antibody or complement. The RBC selectively bound infectious HIV virions as opposed to 
other viral components and removed all infectivity from the suspension medium. The HIV-
binding to erythrocytes was calcium-dependent but complement and CD4-independent. 
Moreover, RBC-bound virions were 100-fold more infectious to CD4 cells than cell-free 
particles(Beck et al., 2009), leading them to conclude that red blood cells could constitute a 
viral reservoir for trans-infection of CD4 cells. The Beck report(Beck et al., 2009) essentially 
confirmed earlier findings by Hess et al(Hess et al., 2002) of a pool of HIV viral RNA 
associated with RBC in HIV-1-infected patients. These included patients in whom plasma 
viraemia had been suppressed to undetectable levels for several months with anti-retroviral 
drugs. Their investigations revealed higher numbers of RNA copies per mL of whole blood in 
the RBC than white cell preparations of the same patients, suggesting that the bulk of the cell-
bound virus circulates on RBC rather than white blood cells (WBC). RBC-bound HIV was also 
able to infect HeLaT4 cells. The number of erythrocyte-bound HIV copies significantly 
correlated with disease severity(Hess et al., 2002). The sum total of these findings is that RBC 
are important elements for consideration in HIV infection and could potentially influence 
epidemiology and clinical progression. 
In order to deal with this reservoir of infection, there is a need to understand the nature of the 
RBC-HIV binding, especially now that there is evidence linking certain blood groups to 
susceptibility or resistance to HIV(Lund et al., 2009, Nneli et al., 2004, Neil et al., 2003, Puri 
et al., 1998).  
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Blood Groups in Other Viral Infections 
The binding of viruses by red blood cells, including specific binding to blood group antigens 
is not unique to HIV, although the mechanisms involved may differ. Noroviruses  have been 
observed to selectively bind to group A, H and difucosylated Lewis blood groups (Nilsson et 
al., 2009, Shirato-Horikoshi et al., 2007), and only volunteers who were secretors of these 
antigens were found to be susceptible to norovirus gastroenteritis(Le Pendu et al., 2006).  
Although this binding was not directly related to red blood cells, it nevertheless demonstrated 
viral affinity for a red blood cell antigen expressed on gastric mucosal cells and led to the 
conclusion that the group A, H and Leb antigens act as viral receptors for the virus(Le Pendu 
et al., 2006, Tan and Jiang, 2005).  
Anaemia 
Anaemia is the most important prognostic indicator in AIDS patients (Mocroft et al., 1999, 
Harris et al., 2008, Olayemi et al., 2008). A large scale study involving over 4000 patients 
established an increasing hazard ratio of 1.42, 2.56 and 5.26 for mild, moderate and severe 
anaemia, respectively (Harris et al., 2008). Various mechanisms have been suggested, 
including bone marrow suppression by various cytokines, toxic depletion by the virus, and 
immune destruction following sensitization with viral proteins (Volberding et al., 2003, Weiss 
and Goodnough, 2005, Beck and Alving, 2011). However, the degree of anaemia has not been 
correlated with the amount of erythrocyte-bound HIV (E-HIV), a phenomenon that might 
account for the autoimmune haemolytic anaemia that commonly occurs in HIV-infected 
individuals. Of interest is the observation by Martins-Silva et al  that HIV infection alters red 
cell and lymphocyte membrane fluidity, membrane protein activity and brings about changes 
in trans-membrane calcium transportation (Martins-Silva et al., 2006). These changes may 
disrupt erythrocyte membrane stability, thus promoting haemolysis and ultimately anaemia.  
Blood group antigens have also been reported to occur on trans-membrane transport channels 
(Telen, 1995). These transport channels have an influence on membrane structure and integrity 
and HIV binding to these transport channels may explain some of the mechanisms that 
contribute to membrane instability with consequent haemolysis and cytopaenias in HIV 
patients. Binding of R5 viruses to CCR5, for example, has been shown to elicit phospholipase 
C production (Fantuzzi et al., 2008). Furthermore, others have reported that phospholipase C 
is translocated to the periphery of activated natural killer (NK) cells with possible role in cell-
mediated cytotoxicity (Ramoni et al., 2001). However, the role of this enzyme in haemolytic 
processes in HIV patients remains a matter for further enquiry. 
The haemolytic effects of phospholipase C could be further aggravated by the presence of 
lipolytic enzymes emanating from the various opportunistic infections. Many bacteria produce 
this lytic enzyme including Mycobacterium tuberculosis, a common opportunistic pathogen in 
HIV patients (Johansen et al., 1996, Côtes et al., 2008, Bakala N'Goma et al., 2010, Schué et 
al., 2010). 
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Conclusion 
Finally, HIV continues to take a toll on the health and economies of the world especially the 
developing countries. To date a cure for this virus continues to be elusive. However, a virtually 
complete remission has been attained in one patient following a bone marrow transplant of a 
CCR5∆32/∆32  mutant cell line (Hütter, 2009). However, despite this milestone, donors with 
this mutation are still far too rare and limited to European populations. The Pk blood group has 
also been demonstrated to offer such protection (Lund et al., 2009). These findings indicate 
that there could be additional blood groups that can be explored in the fight against HIV. Very 
few studies have focused on the role of blood groups in preventing or enhancing HIV infection, 
and these few had the limited scope of only looking at the ABH and Rh(D) blood groups. Africa 
suffers from a lot of malignancies that require total body irradiation and bone marrow 
reconstitution, some of them linked to HIV infection. The occurrence of HIV-resistant blood 
groups may avail bone marrows that may well be an answer to HIV eradication in such cancer 
patients. 
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Abstract 
BACKGROUND: Botswana is among the world’s countries with the highest rates of HIV 
infection. It is not known whether or not this susceptibility to infection is due to genetic factors 
in the population. Accumulating evidence, however, points to the role of erythrocytes as 
potential mediators of infection. We therefore sought to establish the role, if any, of some 
erythrocyte antigens in HIV infection in a cross-section of the population. 
METHODS: 348 HIV-negative samples were obtained from the National Blood Transfusion 
Service as residual samples, while 196 HIV-positive samples were obtained from the 
Botswana-Harvard HIV Reference Laboratory. Samples were grouped for twenty three 
antigens. Chi-square or Fischer Exact analyses were used to compare the frequencies of the 
antigens in the two groups. A stepwise, binary logistic regression was used to study the 
interaction of the various antigens in the light of HIV-status.  
RESULTS: The Rh antigens C and E were associated with HIV-negative status, while blood 
group Jka, P1 and Lu
b were associated with HIV-positive status. A stepwise binary logistic 
regression analysis yielded group C as the most significant protective blood group while Lub 
and P1 were associated with significantly higher odds ratio in favour of HIV-infection. The 
lower-risk-associated group C was significantly lower in Africans compared to published data 
for Caucasians and might explain the difference in susceptibility to HIV-1. 
CONCLUSION: The most influential antigen C, which also appears to be protective, is 
significantly lower in Africans than Caucasians. On the other hand, there are multiple antigens 
associated with increased risk that may override the protective role of C. A study of the 
distribution of these antigens in other populations may shed light on their roles in the HIV 
pandemic. 
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Blood group, HIV risk, Blood group C, Blood Group P1, Blood group Lu
b, Blood group 
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Background 
A number of investigators have alluded to the role of blood groups in HIV epidemiology. 
Arendrup and colleagues, for example, reported that HIV from lymphocytes of blood group A 
individuals was neutralized by anti-A, implying that this mechanism could potentially reduce 
the likelihood of infection in ABO discordant couples (Arendrup et al., 1991). These findings 
were later corroborated by Neil and colleagues (Neil et al., 2003). Furthermore, other 
investigators have reported higher prevalence of HIV-2 in blood group AB (Abdulazeez et al., 
2008), in blood group O (Sayal et al., 1996) as well as a protective function associated with 
blood group Pk (Lund et al., 2009, Lund et al., 2005).  
Many studies have demonstrated the promiscuity of red blood cell antigens in binding to 
bacterial toxins, viruses and other molecules (Branch, 2010, Nilsson et al., 2009, Horakova et 
al., 2004, Lachgar et al., 1998). The Duffy antigen receptor for chemokines (DARC) is the 
receptor for Plasmodium vivax (Barnwell et al., 1989, Hadley and Peiper, 1997) and has 
stimulated debate on its role in HIV-infection as a candidate for HIV-binding and infection of 
susceptible cells (Lachgar et al., 1998, Horne et al., 2009, He et al., 2008, Ramsuran et al., 
2011, Bolton and Garry, 2011). Other reports have suggested that certain erythrocyte lipids 
promote viral membrane fusion with CD4 cells and thus facilitate infection (Puri et al., 1998, 
Puri et al., 2004, Hammache et al., 1999). The predilection of HIV for any particular blood 
group could therefore explain the epidemiology among populations expressing that antigen to 
varying degrees. 
Botswana is one of the countries in the world most hard-hit by the HIV pandemic with 
estimated national prevalence of 17.6%(Agency, 2008) and as high as 33.7% among pregnant 
women aged 15-49 years(Gomez et al., 2007). It is not known whether the susceptibility of this 
population was purely attributable to its social habits or whether there exists a genetic 
predisposition to HIV infection that exacerbated its vulnerability. If indeed erythrocyte surface 
molecules bind and increase the transfection of CD4+ cells, we hypothesize that this should 
reflect, in the prevalence of HIV associated with those erythrocyte surface molecules. Blood 
groups are probably the most abundant molecules on the red blood cell surface and are therefore 
logical candidates for this investigation. We thus sought to find out if the presence of any 
particular blood group antigen could be linked to increased HIV infection risk in Botswana.  
Methods 
Study Population 
Three hundred and forty eight (348) HIV-negative blood samples were obtained from the 
National Blood Transfusion Service (NBTS) as residual samples. The National Blood 
Transfusion Service is the main center for donor recruitment as well as screening for suitability 
of blood donors and for ensuring the safety of donated blood and its components. The NBTS 
blood collections cover the southern part of the country and therefore represents a wide range 
of communities in the Southern part of Botswana. Moreover, Gaborone is a cosmopolitan city 
comprising of individuals from all over the country. Blood donors who tested positive for HIV 
were added to the HIV-positive pool. One hundred and ninety six (196) HIV-positive samples 
were obtained from the Botswana-Harvard HIV Reference Laboratory (BHHRL). This 
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laboratory is a referral laboratory in the management of HIV/AIDS patients and functions 
mainly to support the anti-retroviral treatment programme by providing CD4 counts and viral 
load testing services for prospective and ARV-enrolled patients. All samples were obtained as 
aliquots and assigned new study identification numbers. HIV-positive samples included both 
new cases and those from patients already on anti-retroviral therapy. The total number of 
samples tested for each blood group was determined by the availability of the specific 
antiserum. The HIV-positive samples from the HIV Reference Laboratory covered a wide 
range of communities in the southern eastern part of the country. As stated above, the city of 
Gaborone comprises of individuals from various parts of the country and therefore 
representative of the Botswana population. 
Ethical clearance was obtained from the Ethics Committee of the University of Botswana’s 
Office of Research and Development, Ministry of Health’s Research Unit, BHHRL, Princess 
Marina Hospital Research Committee, and from the Research Ethics Committee of the Faculty 
of Health and Wellness Sciences, Cape Peninsula University of Technology. The study was 
thus approved by the ethics committees of Cape Peninsula University of Technology and 
Botswana’s Ministry of Health. The collection of data was achieved between June 2013 and 
January 2015. Informed consent was not necessary since the research utilized residual samples 
that were rendered anonymous in accordance with the requirements of ISO 15189 
(Standardisation, 2007). 
Determination of Blood Groups 
Patient and donor red cells were phenotyped using specific antisera (Fortress Diagnostics, 
Antrim, United Kingdom). Blood grouping was done following routine tube-grouping 
technique as outlined in the manufacturer’s instructions for all blood groups, with the exception 
of anti-Jka and Jkb which failed quality control unless subjected to the indirect antihuman 
globulin procedure (AHG). It was reasonable to subject them to AHG since they are also known 
to be non-agglutinating antibodies. The AHG procedure was used to determine the reactivity 
of the following antibodies: anti-Fya, anti-Fyb anti-Jka, anti-Jkb, anti-Kpa, anti-Kpb, anti-Lua, 
anti-Lub, Anti-S and anti-s. The AHG was also used to confirm negative results for anti-D. The 
specificity and reactivity of the antisera was confirmed by use of an antibody identification 
panel, DiaPanel®, Lot 16211.66.x-16311.66.x (BioRad®, Japan). The blood antigens tested for 
in this study included: A, B, “O”, D, C, c, E, e, Fya, Fyb, Jka, Jkb, Kpa, Kpb, Lea, Leb, Lua, Lub, 
M, N, P1, S, and s. 
 
Statistical Analysis 
Data analysis was conducted using IBM SPSS version 23 software. Frequencies were used to 
report blood group prevalence. Comparison of proportions of blood group antigens between 
HIV-infected and non-infected individuals were conducted using Pearson’s chi-square test (χ2) 
or Fisher’s exact test where appropriate. We explored the combined effect of various blood 
groups on HIV prevalence using a stepwise binary logistic regression analysis. Only blood 
group antigens with statistically significant association with HIV status in bivariate analyses 
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were included in the model and the results were reported as odds ratio with 95% confidence 
interval. Results were considered significant at p < 0.05. 
Results  
In total, 348 HIV-negative blood samples and 196 blood samples from HIV-infected patients 
were studied. The results comparing the prevalence of each antigen in the HIV group versus 
uninfected controls are summarized in Table 3.1. The frequency of C Rh antigen was lower in 
HIV-infected patients than in HIV-negative subjects, 17.1% (95% CI 10.7 – 23.5) versus 29.7% 
(95% CI 24.1 – 35.1), respectively p = 0.006.  Similarly, the E Rh antigen was lower in HIV-
infected patients than in HIV-negative subjects, 12.1% (95% CI 6.6 – 17.6) versus 21.2% (95% 
CI 16.2 – 26.2), respectively p = 0.024.  Only these Rh-antigens raised the prospects of a 
protective function against HIV-1 infection. 
In contrast, the HIV-infected group exhibited a significantly higher prevalence of blood groups 
Jka , Lub and P1 compared to HIV-negative individuals, suggesting a potential infection risk 
associated with carriage of these antigens. Among the HIV-infected patients the prevalence of 
Jka was 85.3% ((95% CI 78.7 – 91.9) compared to 51.4% (95% CI 41.8 – 61.0) in non-infected 
individuals, p = 0.024. The prevalence of Lub was 86.7% (95% CI 80.3 – 93.1) among HIV 
patients versus 67.8% (95% CI 61.8 – 73.8) in non-HIV infected subjects, p = 0.0001. Among 
the HIV-infected patients, P1 prevalence was 89.2% (95% CI 83.1 – 95.3) compared to 74.6% 
(95% CI 69.1 – 80.1), p = 0.003.  All the other 19 red cell antigens we tested were not 
significantly different when stratified according to HIV status.  
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Table 3. 1 – Prevalence of blood group antigens in HIV-infected and uninfected subjects 
Antigen HIV-positive Subjects HIV-negative Subjects  
 
P-value 
  
N 
Antigen Frequency 
%  (95% CI) 
 
N 
Antigen Frequency 
%  (95% CI) 
A 155 34.1 (26.5 – 41.7) 239 42.3 (35.9 – 48.7)   0.109 
B 155 32.3 (24.8 – 39.8) 239 25.9 (20.2 – 31.6)   0.174 
O 239 41.3 (47.3 – 65.9) 336 41.0 (35.6 – 46.4)   1.000 
D 155 95.5 (92.2 – 98.8) 239 97.1 (94.9 – 99.3)   0.406 
C 140 17.1 (10.7 – 23.5) 269 29.7 (24.1 – 35.3)   0.006 
c 140 99.3 (97.9 – 100.7) 269 97.4 (95.5 – 99.3)   0.273 
E 140 12.1 (6.6 – 17.6) 269 21.2 (16.2 – 26.2)   0.024 
e 140 99.3 (97.9 – 100.7) 269 98.5 (97.0 – 100)   0.665 
Fya 146 10.3 (5.3 – 15.3) 251 9.6 (5.9 – 13.3)     0.818 
Fyb 146 12.3 (6.9 – 17.7) 254 9.8 (6.1 – 13.5) 0.440 
Jka 116 85.3 (78.7 – 91.9) 109 51.4 (41.8 – 61.0) <0.0001 
Jkb 117 25.6 (17.5 – 33.7) 109 31.2 (22.3 – 40.1) 0.355 
Kpa 123 2.5 (-0.3 – 5.3) 264 1.1 (-0.2 – 2.4)     0.387 
Kpb 97 45.4 (35.3 – 55.5) 266 36.5 (30.6 – 42.4) 0.124 
Lea 82 30.5 (20.3 – 40.7) 257 25.3 (19.9 – 30.7) 0.354 
Leb 66 50.0 (37.7 – 62.3) 257 42.0 (35.8 – 48.2) 0.244 
Lua 118 1.7 (-0.7 – 4.1) 266 3.8 (1.5 – 6.1) 0.358 
Lub 113 86.7 (80.3 – 93.1) 240 67.8 (61.8 – 73.8)   0.0001 
M 92 77.2 (68.5 – 85.9) 236 80.9 (75.8 – 86.0)    0.456 
N 93 71.0 (61.6 – 80.4) 269 66.9 (61.2 – 72.6) 0.470 
P1 105 89.2 (83.1 – 95.3) 248 74.6 (69.1 – 80.1) 0.003 
S 125 33.6 (25.2 – 42.0) 225 31.6 (25.4 – 37.8) 0.695 
s 111 95.6 (91.7 – 99.5) 226 89.4 (85.3 – 93.5) 0.060 
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We also investigated the possible combined influence of the protective and risk-associated 
blood group antigens on HIV status. For this purpose, data was subjected to a stepwise logistic 
regression model in which analysis was repeated after the systematic removal of the least 
significant among the covariates. In this model, only those blood groups that were significantly 
associated with HIV infection in bivariate analyses were tested. The results of this analysis are 
shown in Table 3.2. 
Table 3. 2 – Logistic regression model showing the effect of blood group antigens on the risk 
of HIV infection 
Antigen Odds Ratio (95% Confidence Interval) P-value 
E 0.859 (0.169 - 0.437) 0.855 
P1 0.428 (0.108 – 0.169) 0.226 
C 0.146 (0.047 – 0.455) 0.001 
Jka 1.001 (0.156 – 6.408) 1.0 
Lub 1.731 (0.314 – 9.541 0.529 
 
After the stepwise elimination process, only the C, Lub and P1 maintained statistical 
significance as risk factors in the model. The results are shown in Table 3.3. Carriage of P1 
antigen increased the odds of HIV infection by 2.2 (95% CI 1.1 – 4.5), p = 0.026 and similarly, 
carriage of Lub increased the odds ratio for HIV infection by 2.9 (95% CI 1.5 – 5.5), p = 0.001. 
Conversely, presence of C Rh antigen resulted in 40% decrease in HIV risk of infection.  
 
Table 3. 3 – Blood group antigens associated with HIV infection in multivariate logistic 
regression analysis 
Antigen Odds Ratio (95% Confidence Interval)) p-value 
C 0.6 (0.3 – 1.0) 0.047 
P1 2.2 (1.1 – 4.5) 0.026 
Lub 2.9 (1.5 – 5.5) 0.001 
 
We further sought to determine if the frequency of protective and risk-associated antigens was 
any different from other populations of African ethnicity or Caucasian counterparts. The 
frequency of blood group C in this study, though not statistically different from that published 
for Blacks (p=0.8389), was much lower than that for Caucasians (p<0.0001)(Makroo et al., 
2013) The frequencies for the risk-associated P1 and Lu
b were also lower in this study than in 
Caucasians (p=0.0446 and p<0.0001, respectively (Hellberg, 2007, Badjie and Stubbs, 2012, 
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Hellberg et al., 2013). However, these other studies did not report on the HIV status of the 
populations from which the data was derived. 
Discussion 
Blood groups have been implicated as factors in the epidemiology of HIV(Arendrup et al., 
1991, Bolton and Garry, 2011, Lachgar et al., 1998, Onsten et al., 2013, Puri et al., 1998, 
Ramsuran et al., 2011). We studied the distribution of blood groups in Botswana and identified 
those associated with HIV infection. We therefore determined the frequencies for ABO, Rh, 
Kidd, Kell, Duffy, Lewis, Lutheran, MNSs, and P1 blood group systems in both HIV-infected 
patients and non-HIV-infected individuals. The frequencies of Fyb, Jka, Jkb, Kpb, Leb, N, P1, 
Lub and s in Botswana were statistically lower than the published literature for Blacks (Badjie 
and Stubbs, 2012, Makroo et al., 2013, Cooling, 2011). This is not a surprising finding since 
blood group variations do occur within a population (Badjie and Stubbs, 2012) and may 
sometimes be aggravated by cultural marriage practices that promote peculiar phenotypes 
(Mavanga et al., 2013). Recent publications have also demonstrated the peculiarities of the 
Botswana population that necessitate the use of Botswana-specific reference values (Mine et 
al., 2011, Maphephu and Kasvosve, 2011, Segolodi et al., 2014). Other than these, the rest of 
the antigen frequencies were consistent with published literature as noted. 
The C and E antigens in the Rhesus blood group system were found to be rarer in HIV-infected 
subjects while that of Jka, Lub and P1, were more prevalent in this group. In comparison to 
individuals of African ethnicity, the Botswana population does not appear to have any higher 
frequency of risk-associated blood groups nor does it have any lower frequency of those 
associated risk mitigation. However, the prevalence of the risk-mitigating antigen C was lower 
in blacks (and in the Botswana population studied) than in Caucasians or Asians. Given the 
strength of the influence of this antigen in the model used, and given the relative rarity of its 
frequency in the Botswana population, we conclude that the C antigen likely plays an important 
role in mitigating against HIV-1 infection and could have played a role in the HIV pandemic 
in Botswana.  
We hypothesized that a higher prevalence of an antigen in the HIV+ group than the control 
group possibly indicates that its presence promotes HIV infection, and vice versa.  We therefore 
investigated the potential mitigation of the “protective” phenotypes against the “risky” ones. 
The odds ratios were therefore computed for risk-associated blood groups in the presence or 
absence of Rh C or E expression. The presence of C or E did not consistently result in 
obliteration of the risk-significance in the risk-associated phenotypes. This analysis was also 
hampered by the simultaneous carriage or alternate carriage of suspect antigens in different 
individuals, making it difficult to isolate the effect of each antigen. 
To further elucidate how the odds ratio is impacted by interaction of all significant blood 
groups, the data was subjected to a logistic regression analysis. The Jka and E antigens, 
although highly significant in their association to HIV infection in the isolated Chi-square 
analysis, failed to maintain significance in the logistic regression model. On the other hand, the 
C, P1 and Lu
b remained significant with C significantly reducing the odds of HIV infection 
while P1 and Lu
b increased the odds of infection.  
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Our results for blood group O are not in concordance with the reports by other investigators 
(Nneli et al., 2004, Sayal et al., 1996) who documented an increased HIV susceptibility for this 
group. Neither did we find any increased risk in group B individuals as reported in Brazil 
(Onsten et al., 2013). There was also no difference in HIV prevalence between D-positive and 
D-negative subjects as reported in Nigeria (Abdulazeez et al., 2008). However, we take 
cognizance of the possible population differences and the effect of other factors such as viral 
strains in those populations that may account for the disparities observed. But for the Botswana 
population, the ABO groups do not appear to have any role in enhancing or diminishing HIV 
risk of infection. 
Our findings indicate that P1 antigen, a glycosphingolipid, is associated with a higher risk of 
HIV infection and thus corroborates the role of glycosphingolipids as facilitators of viral fusion 
to CD4+ cells (Hammache et al., 1999, Puri et al., 2004). In their experiments, Puri and 
colleagues demonstrated that HIV infection of CD4+ cells could be averted by addition of a 
glycosphingolipid inhibitor. Conversely, the presence of the glycosphingolipid increased 
susceptibility of CD4+ cells to HIV infection. The P1 antigen is also known to bind several 
microorganisms including enteropathogenic Escherichia coli and  parvovirus (Branch, 2010) 
and has a wide tissue distribution (Hellberg et al., 2013), providing multiple opportunities for 
viral binding.  It is conceivable from its broad spectrum of binding that P1 could also bind and 
act as a receptor for HIV. We conclude that our findings corroborate the role of P1 as a potential 
aggravator of HIV infection. 
We did not find any risks associated with the Duffy blood group system or its Duffy-null 
phenotype alluded to elsewhere (Thobakgale and Ndung'u, 2014, Ramsuran et al., 2011, He et 
al., 2008, Lachgar et al., 1998). Our results in this respect appear to support an insignificant 
role of Duffy blood group expression consistent with other investigators(Winkler et al., 2009, 
Horne et al., 2009). However, we did confirm that the Duffy-null phenotype was associated 
with leukopenia(Reich et al., 2009), though not neutropenia, in Botswana.   
The Lutheran blood group is a member of the immunoglobulin superfamily and has been shown 
to function as a receptor for laminin (Parsons et al., 1995, Nemer et al.) with potential role for 
signal transduction and is widely distributed in various tissues (Parsons et al., 1995, Eyler and 
Telen, 2006) No data is available on the role of the Lutheran blood groups in HIV infection. 
However, its tissue-wide distribution would facilitate infection at various anatomic sites, if 
such a role could be confirmed.  
Conclusion 
We have studied the role of 23 blood group antigens in relation to susceptibility to HIV 
infection, this being hitherto the most comprehensive study on the role of blood groups in HIV 
infection. The strongest association in this study was with the Rh antigen C, which also appears 
to be protective, and is significantly lower in Africans than Caucasians. On the other hand, 
there are multiple antigens associated with increased risk that may override the protective role 
of C. A study of the distribution of these antigens in other populations may shed light on their 
roles in the HIV pandemic. 
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Abstract: 
Atheromatous lesions are formed by macrophage and LDL-cholesterol invading the vascular 
intima. Here we show that increasing cholesterol levels are associated with peripheral monocyte 
depletion and this imbalance is aggravated by carriage of Lu/BCAM leukocyte adhesion 
molecule. This is true only in HIV infection and probably explains the risk of atherosclerosis 
observed in HIV infection.  
Key words: Cholesterol, Non-DHL cholesterol, Lu/BCAM, atherosclerosis  
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Introduction 
The pathology of atherosclerosis is tightly linked to three main factors; leukocytes, plasma 
lipids and vascular injury or chronic inflammation (Frostegard et al., 1990, Oh et al., 2009b). 
Leukocytes such as neutrophils, activated monocytes or monocyte-derived macrophages and 
platelets accumulate in the vascular sub-endothelial matrix by use of adhesion molecules. The 
Lutheran blood group, also known as basal cell adhesion molecule (Lu/BCAM), is one such 
molecule and is expressed on both monocytes and endothelial cells (Pedraza et al., 2000). It is 
the natural ligand for laminin, an extracellular basement membrane protein that facilitates both 
adhesion and extravasation of monocytes (Pedraza et al., 2000). In addition, monocytes and 
neutrophils also constitutively express α4β1 integrin (Chaar et al., 2010), another ligand for 
Lu/BCAM.  These molecules enable these cells to adhere to the endothelium and have been 
implicated in the pathology of crescentic, sickle cell disease (Chaar et al., 2010) as well as in 
several cancers suggesting more efficient tumour tethering and greater tumour size (Chang et 
al., 2017, De Grandis et al., 2013).   
In HIV-infected individuals, the viral Tat protein accumulates in the extracellular matrix of 
blood vessels and facilitates integrin-mediated adhesion (Chiodelli et al., 2012) with the 
consequence that HIV-infected monocytes have enhanced extravasation (Dhawan et al., 1992).  
HIV infection is also characterised by chronic inflammation resulting from the activation of T-
cells, macrophages, neutrophils and NK cells– all of which release pro-inflammatory cytokines 
that create a state of persistent inflammation (Appay and Sauce, 2008). This chronic 
inflammation involves neutrophils which produce reactive oxygen species thought to 
contribute to the oxidation of LDL-C (Hartwig et al., 2015). Cholesterol enrichment of 
neutrophil membranes results in more stabilized rolling and adhesion on endothelial cells (Oh 
et al., 2009a), where they may recruit monocytes (Hartwig et al., 2015) to promote 
atherogenesis. In particular, non-HDL cholesterol has been documented as one of the more 
important promoters of atherosclerosis in HIV-infected patients (Badiou et al., 2008). The 
atheromatous lesion forms by gradual accumulation of oxidized LDL-C and infiltration by 
macrophages, smooth muscle cells and platelets (Østerud and Bjørklid, 2003). This may 
ultimately narrow the vascular lumen, causing tissue hypoxia distal to the atheroma. Moreover, 
the release of RANTES (CCL5) by activated platelets in the atheroma leads to further 
recruitment of monocytes and neutrophils (von Hundelshausen et al., 2001). A high monocyte 
count has thus been reported to be a long term predictor of plaque-formation (Johnsen et al., 
2005), while neutrophil enzymes such as elastase and myeloperoxidase in the atheroma may 
destabilize it (Ionita et al., 2010), leading to its fragmentation and subsequent generation of 
emboli that may cause vascular occlusion at distant sites.  
In our previous study, the Lutheran blood group, Lub, was associated with a three-fold risk for 
HIV infection (Motswaledi et al., 2016), and it was suspected that this could be due to its 
adhesiveness that promotes trans-endothelial migration and spread of infected monocytes to 
distant sites. The current study therefore sought to determine the effect, if any, of carriage of 
the Lub antigen as an adhesion molecule on circulating monocytes and neutrophils as well as 
how these parameters related to cholesterol measurements. The results indicate that HIV does 
affect the relationship between monocytes and cholesterol, and that this relationship is 
accentuated by expression of Lub antigen. 
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 Materials and Methods 
One hundred and one (101) blood samples comprising 59 females and 42 males received at 
Julia Molefe Clinic in Gaborone were enrolled on the study between December 2016 and 
January 2017. The patients had all tested positive for HIV and were being prepared for 
enrolment into the antiretroviral therapy programme. A full blood count (FBC) was done using 
the Sysmex ® XT1800i haematology analyser (Sysmex Corporation, Kobe, Japan). The 
samples were phenotyped for the Lutheran antigens (Lua and Lub) using specific antisera 
(Fortress Diagnostics, Antrim, United Kingdom) according to the manufacturer’s instructions. 
The reactivity of the antisera was confirmed by use of antigen-positive and negative cells 
selected from an antibody identification panel (DiaPanel®, Lot 45241.88.1, Bio-Rad®, 
Cressier FR, Switzerland). Total and HDL-cholesterol measurements were also made using the 
AU480 Chemistry analyser (Brea, CA). LDL cholesterol was calculated using the Friedewald 
equation. We also revisited a previous dataset of 261 normal subjects as a control group to 
examine the same relationships in healthy, HIV-uninfected subjects(Mine et al., 2011).  
Ethical clearance for the study was obtained from the Office of Research and Development 
(University of Botswana), Botswana’s Ministry of Health and Wellness’s Health Research 
Development Committee and Faculty of Health and Wellness’ Research Ethics Committee 
(Cape Peninsula University of Technology)[Appendices A-C]. Informed consent was not 
necessary since de-identified, residual samples were used (ISO, 2007).  
The results were analysed using the IBM SPSS version 24 statistical software. Statistical 
analyses included comparison of means according to carriage of the Lutheran antigens, as well 
as correlation of data to explore relationship between variables. Results were considered 
significant only if P<0.05. 
Results: 
An inverse correlation was observed between total cholesterol and absolute monocyte and 
neutrophil counts (See Table 4.1). In HIV-infected subjects, monocyte depletion was 
associated with relatively high LDL-cholesterol levels (r=-0.435, p=0.003). The correlation 
was stronger (r=-0.479, p=0.010) in Lub-positive but absent (r=-0.212, p=0.414) in those 
negative for the antigen. Among controls (n=261), LDL cholesterol did not correlate with 
monocyte counts at all (r=0.031, p=0.619). Lub expression was associated with lower absolute 
monocyte counts (0.46±0.19 versus 0.54±0.22x109/L, p=0.040).   
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Table 4.1:  Correlation of cholesterol with phagocyte counts in Lub-positive and negative 
subjects 
Test on Mean±SD 
(x109/L) 
Pearson correlation 
coefficient  (r) with 
TC 
P-value 
Lub –positive and negative subjects (n=101) 
Absolute neutrophil count   2.7±2.0 -0.207 0.038 
Absolute  monocyte count 0.48±0.20 -0.253 0.011 
Lub-positive subjects only (n=76) 
Absolute neutrophil count  2.65±2.2 -0.310 0.006 
Absolute Monocyte count 0.46±0.20 -0.330 0.004 
Lub-negative subjects only (n=25)  
Absolute neutrophil count 2.8±1.3 0.153 0.465 
Absolute Monocyte count 0.54±0.22 -0.047 0.822 
 
To further elucidate the total cholesterol (TC) component responsible for these observations, 
correlations were done involving phagocyte counts versus HDL-C and non-HDL-C. Non-
HDL-C was consistently associated with a lower monocyte count suggesting that the 
leukocyte-depleting effects of cholesterol are largely due to non-HDL-C and that depletion is 
enhanced in Lub-positive subjects. Neutrophils were less affected by non-HDL-C than 
monocytes (See Table 4.2). 
Table 4. 2: Correlation of phagocyte counts with non-HDL cholesterol in Lub-positive and 
negative subjects 
Test on Mean±SD Non-HDL 
Correlation 
coefficient  (r) 
P-value 
Lub –positive and negative subjects (n=59) 
Absolute neutrophil count  (x109/L) 2.70±2.00 -0.226 0.136 
Absolute  monocyte count (x109/L) 0.48±0.20 -0.401 0.006 
In Lub-positive subjects (n=28) 
Absolute neutrophil count (x109/L) 2.65±2.20 -0.369 0.053 
Absolute Monocyte count (x109/L) 0.46±0.20 -0.422 0.018 
In Lub-negative subjects (n=31) 
Absolute neutrophil count (x109/L) 2.85±1.30 0.143 0.584 
Absolute Monocyte count (x109/L) 0.54±0.21 -0.259 0.315 
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Discussion 
We studied the relationship between cholesterol and phagocytes (monocytes and neutrophils) 
in HIV-1-infected and uninfected individuals in an attempt to determine the influence, if any, 
of the Lu/BCAM on phagocyte counts.  
We hypothesized that carriage of the Lub antigen, an adhesion molecule, would enhance 
margination of leukocytes leading to a peripheral deficiency of the affected leukocytes. Indeed, 
we observed a significantly lower absolute monocyte count in Lub-positive individuals 
compared to Lub-negatives.  
We also observed a negative correlation between cholesterol and phagocytes (neutrophils and 
monocytes), which corroborates the findings by other investigators that membrane cholesterol, 
which is in equilibrium with plasma cholesterol (Buchwald et al., 2000), increases leukocyte 
adhesion and extravasation (Oh et al., 2009b, Frostegard et al., 1990). Moreover, phagocyte 
counts were negatively correlated with non-HDL-C and LDL-C, which lipids are known to 
promote adhesion and atherogenesis (Frostegard et al., 1990, Østerud and Bjørklid, 2003). The 
monocyte depletive effect of cholesterol was accentuated in Lub-positive subjects but totally 
absent in the Lub-negative subjects. We conclude that higher levels of cholesterol are associated 
with lower peripheral monocyte and neutrophil counts and that this depletion is accentuated in 
individuals expressing the Lub antigen. This depletion is an effect of HIV infection since it was 
not observed in the uninfected population, and probably involves the  particular role of the 
HIV-Tat protein’s enhancement of vascular adhesion and trans-endothelial migration of 
monocytes reported by other investigators (Lafrenie et al., 1996). HIV-infected monocytes are 
known to migrate more efficiently across vessel wall while maintaining their infectivity 
(Dhawan et al., 1992). We conclude that the Lub blood group contributes to the depletion of 
circulating phagocytes, possibly by enhancing their margination and extravasation (Oh et al., 
2009b). 
Working from the established fact that cholesterol, especially LDL-C, promotes adhesion of 
phagocytes (Oh et al., 2009a, Frostegard et al., 1990), with possible reduction of peripheral 
counts, we noted that in HIV infection, even normal cholesterol levels are associated with 
diminishing circulating phagocytic cells. This could be due to the chronic inflammatory status 
occasioned by HIV infection. It appears, therefore, that HIV-infected individuals are at higher 
risk of developing cholesterol-related monocytopenia and neutropenia, which, in the presence 
of increased non-HDL cholesterol, points to the peculiar vulnerability of HIV-infected patients 
to cardiovascular diseases. Although these observations were generally expected considering 
that cholesterol promotes tethering of phagocytes to the endothelium (Oh et al., 2009b, Dhawan 
et al., 1992), it was interesting that only in HIV infection was the phagocyte-depleting effect 
of cholesterol significant. 
When cholesterol components were examined, non-HDL-C negatively affected phagocyte 
counts consistently, especially the monocyte counts, which finding corroborated previous 
reports by (Badiou et al., 2008) linking non-HDL-C to atherosclerosis in HIV infection.   
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Conclusion  
Our findings suggest that the risk of cardiovascular disease in HIV-1-infected subjects may in 
part be due to an interplay between cholesterol, phagocytes and Lub-mediated adhesion, all of 
which tend to recruit phagocytes out of circulation. While a genetic predisposition for 
atherogenesis has always been alluded to, our results suggest the Lub adhesion molecule to be 
a potentially important genetic link. The results of this study also imply a need to manage 
cholesterol in HIV-infected patients to achieve lower levels than the general public, especially 
for those who are Lub-positive. Moreover, the vulnerability occasioned by the Lub-positive 
status may provide opportunity for personalized care in Lub-positive, HIV-infected individuals. 
A limitation of our study was that we did not directly measure phagocyte migration but rather, 
implied phagocyte migration from diminished peripheral cell counts. Future studies need to 
focus on direct migration measurements of phenotyped phagocytes.   
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Abstract 
BACKGROUND: Sub-Saharan Africa and the Caribbean countries bear a disproportionate 
burden of the HIV pandemic. This suggests a genetic predisposition arising from a common 
ancestry. We previously reported a 40% HIV risk-reduction associated with RHCE*C blood 
group. The current study sought to elucidate potential mechanisms for this risk reduction. 
MATERIALS AND METHODS: Lymphocyte sub-populations and viral load measurements 
were achieved by routine diagnostic laboratory methods in 102 untreated, HIV-1 infected 
patients. Results were compared across categories of RHCE*C blood group. 
RESULTS: Carriage of the RHCE*C antigen was associated with a higher proportion of T-
cells (82±8% versus 75±10%, p=0.001), especially single-positive (CD8+) cytotoxic T-cells 
(64±14 versus 54±13%, P=0.004). High absolute CD8 counts were more prevalent among C-
positive than C-negative subjects (90% versus 65%, p=0.023). Among C-positive subjects, the 
increase in CD8 count paralleled viral load compared to C-negatives (r2=0.630, p<0.0001 
versus r2=0.148, p<0.001, respectively). Moreover, examination of data involving 20 countries 
or regions indicated that high HIV prevalence occurred only in those countries with RHCE*C 
frequencies lower than 30% (χ2=20.0, p<0.0001).  
DISCUSSION: Results suggest that RHCE*C enhances CD8 counts in HIV infection, which 
cells are known to play a vital role in immunity against HIV. Invariably, the only geographical 
locations with high HIV prevalence rates are those where the frequency of this antigen is low. 
Results provide a possible genetic explanation for the worldwide distribution of the HIV 
pandemic, with a special emphasis on the vulnerability of individuals of African descent, where 
the prevalence of RHCE*C is consistently low across many countries. 
Keywords: HIV-prevalence; RHCE*C / RHCE*C; CD8 count; CD4 count; viral load; African. 
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Introduction 
HIV prevalence in Botswana is among the highest in the world (Weiser et al., 2006). Many 
studies have revealed risk factors that have contributed to the spread of the virus, some of which 
include poverty, multiple sexual partners, alcohol and drug abuse as well as improper use of 
condoms (Keetile, 2014). Excessive alcohol consumption was reported as the greatest risk 
since it promoted risky behaviours in general (Weiser et al., 2006). In some studies, the risk of 
infection in women, especially in Botswana and Swaziland, was reported to be due in part to 
cultural norms that predispose women to sexual abuse or assign them to lower economic status 
(Shannon et al., 2012).  
The high prevalence of HIV in Africa as well as those communities comprising of people of 
African descent, such as the Caribbean strongly suggests a common genetic link. However, 
few such links have been alluded to. In at least two studies, the Duffy antigen receptor for 
chemokines, was reported to promote HIV infection (He et al., 2008, Lachgar et al., 1998) 
among Africans. However, these reports were strongly refuted by other  investigators (Winkler 
et al., 2009).  In yet another study, the Pk blood group was reported to protect against HIV 
infection (Lund et al., 2009). However, this antigen is rare among Africans (Cooling, 2014). 
While it is generally accepted that host genetic factors play a role in immunity against the virus 
(Chatterjee, 2010), no specific hereditary factors have been advanced to explain the pandemic 
in Africa.  
Although the function of many blood groups remains unknown, some reports have 
demonstrated that erythrocytes bind HIV and that such HIV becomes more efficiently 
transferred to CD4+(Beck et al., 2009, Beck et al., 2013, Garcia et al., 2012) cells. Erythrocyte 
antigens are therefore logical targets for erythrocyte-virus interactions. In our previous work, 
we reported a 40% risk reduction for HIV-1 infection in individuals of  the RHCE*C blood 
group (also denoted as RHCE*C), while blood groups P1 and Lu
b were associated with double 
and triple risks, respectively (Motswaledi et al., 2016). Of epidemiological importance was the 
observation that this protective blood group was very rare among Africans, while the risk-
associated blood groups were much more common, raising the question of whether this 
antigenic profile could have contributed to the peculiar susceptibility of this population to 
infection with HIV-1. 
RHCE*C is a component of the Rh blood group system. Antigens in this system are inherited 
in strong linkage disequilibrium on chromosome 1.  The RHD gene codes for the D antigen 
while the RHCE gene caries a polymorphism that leads to the production of a range of RH 
phenotypes that include CE, Ce, cE or ce (Ripoche et al., 2004). The Rh gene products are 
organized on the erythrocyte membrane as a complex of proteins that include the Rh-associated 
glycoproteins (RhAG), LW, CD77, Duffy and CD47, which serve as ammonia transporters 
(Ripoche et al., 2004, Anstee and Tanner, 1993, Pourazar, 2007).  
In the current study, we performed viral load, CD4 and CD8 counts and compared them among 
patients expressing or negative for RHCE*C. From these results and the review of available 
literature, we sought to find out if the observed risk reduction for HIV infection could be 
corroborated by clinical laboratory data.  
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Materials and methods 
One hundred and twenty (120) HIV-1-infected (48 males and 72 females) treatment-naïve 
(self-reported) individuals were enrolled in the study. Since, no drug tests were done to verify 
their treatment-naïve status, 19 subjects with undetectable viral load were excluded on the 
presumption that they could be on treatment.  
We used anonymized EDTA-anticoagulated samples from the Botswana-Harvard HIV 
Reference Laboratory in Gaborone. Ethical clearance was obtained from the University of 
Botswana’s Office of Research and Development, Human Research and Development 
Committee of the Ministry of Health and Wellness, Gaborone District Health Management 
Team and the Research Ethics Committee of the Faculty of Health and Wellness Sciences at 
Cape Peninsula University of Technology. Individual consent was not needed since the study 
used anonymized, residual samples (ISO, 2007). 
The viral load was measured using the Cobas® Taqman 48 analyser (Pleasanton, CA., USA). 
CD3, CD4, CD8 and CD45 counts obtained using the FacsCalibur ® flow cytometer (Becton-
Dickinson, San Jose, CA, USA). The samples were further phenotyped for the C antigen using 
specific anti-C and anti-c antibodies (Fortress Diagnostics, Antrim, UK). The reactivity of the 
antisera was confirmed with C-positive and negative cells selected from an antibody 
identification panel, Bio-Rad DiaPanel®, Lot 45241.88.1, (Cressier FR, Switzerland). 
Results of  laboratory tests were interpreted in line with the reference ranges previously 
determined for the Botswana population (Mine et al., 2011).  
The results were analyzed using the IBM SPSS version 24 statistical software. Correlations 
were used to study the effect of blood RHCE*C on the relationship between CD8%, log viral 
load, CD8% and CD4%. Results were considered significant only if P<0.05. 
Results 
Results from experimental data 
The mean viral load did not differ between individuals positive (n=21) or negative (n=81) for 
C (p=0.398). In untreated, HIV-1-infected subjects, the CD4 count was significantly lower than 
that of the general uninfected population. On the contrary, the absolute CD8 count was 
significantly higher in the infected than uninfected subjects. The results are shown in Table 
5.1.   
  
45 
 
 
Table 5.1: Comparison of CD4 and CD8 in untreated, HIV-infected individuals and normal 
controls.  
Lymphocyte 
population 
Mean in HIV-infected 
Subjects (n=101) 
Mean in  normal 
population  
(n=261) 
P-value 
CD4+ 307±208 859* <0.0001 
CD8+ 927±492 540* <0.0001 
*One sample (T-test) mean used from a previous study(Mine et al., 2011). 
In individuals expressing the RHCE*C antigen, 19/21 had a high absolute CD8 count compared 
to 52/80 who were RHCE*C-negative. A high CD8 count was therefore more associated with 
C-positive individuals than C-negative (90% versus 65%, p=0.023). The mean CD8 count 
between the two categories of RHCE*C, though higher in the C-positive group, did not reach 
statistical significance. However, the proportion of T-lymphocytes (CD3+) and cytotoxic 
(CD8+) T-cells was higher in the C-positive population as reflected in Table 5.2.  
Table 5.2: Comparison of mean Lymphocyte sub-populations in untreated HIV-infected 
patients according to RhC phenotype. The RhC phenotype was associated with higher CD8 
counts. 
Lymphocyte Sub-
population 
C-Positive 
(Mean±SD) n = 21 
C-Negative 
(Mean±SD) 
n = 80 
P-value 
      CD3+ (%) 82±8 75.0±10 0.001 
      CD8+ (%) 64±14 54±13 0.004 
CD8 Absolute 
count (/µL) 
1058±444 893±500 0.171 
 
Among C-positive subjects, the increase in CD8 counts paralleled viral load more strongly 
than in C-negatives (r2=0.630, p<0.0001 versus r2=0.148, p<0.001, respectively). These 
results are shown in Fig 5.1. 
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Figure 5.1: Relationship between viral load and CD8% in C-positive subjects shows strong 
positive correlation (A: r2=0.148, p<0.001, versus B: r2=0.630, p<0.0001) 
Results from country HIV prevalence data 
A literature search was also undertaken to investigate HIV prevalence in countries where the 
frequencies of the RHCE*C are known. Data was obtained for 20 countries or communities as 
shown in Table 5.3. In brief, a high HIV prevalence in any country or community was 
associated with an RHCE*C frequency less than 30% (Pearson χ2=20.0, p<0.0001).  
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Table 5.3: Comparison of RHCE*C with HIV prevalence across geographical regions 
Country/Community RHCE*C 
Frequency 
HIV Prevalence 
Botswana 29.70 21.90 
South Africa (Blacks) 18.80 18.90 
Nigeria 28.2 2.9* 
Cote d'Ivoire 21.97 2.70 
Caribbean 24.50 1.60** 
Uganda 3.62 6.5*** 
Thailand 51.50 1.10 
Ethiopia (Blacks) 41.18 1.10 
South Africa (Asians) 99.53 1.00 
Mali 58.8 1.00 
Brazil 63 0.6 
Mauritania 42.69 0.5 
Argentina 62 0.4 
Laos 60.30 0.30 
Southern India 88.00 0.30 
Northern India 84.76 0.26 
Sudan 58.40 0.20 
Netherlands 68.00 0.20 
Iran 75.90 0.10 
China 78.22 0.04 
*5.8% in 2001. Some states at some point exceeded 8%, and current rates may only reflect the 
effect of treatment. Nevertheless, Nigeria carries the world’s heaviest HIV burden (Gwaram, 
2013). 
**Prevalence rates range from 1-5% for different islands, depending on the reporting dates 
(Coggins, 2006, UNAIDS, 2016a). RHCE*C information for Curacao used here. 
***Prevalence is down from 24.8% in 1994 (Kilian et al., 1999) 
 
Discussion 
RHCE*C, CD8 Parameters and protection against HIV infection 
This study sought to establish the mechanism of protection provided by carriage of RHCE*C 
observed in a previous study. In this study, expression of this antigen was associated with a 
higher proportion of cytotoxic (CD8+) T-cells (CTL). In C-positive subjects, the CD8 absolute 
count varied in direct proportion to the viral load, suggesting a coordinated response to viremia. 
This correlation was much weaker in the C-negative group.  Moreover, the proportion of 
individuals with high CD8 counts was greater in the C-positive group. All these observations 
suggest a role for this antigen in cytotoxic T-cell kinetics and function, and may therefore 
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explain the protective role of this blood group observed in our previous study (Motswaledi et 
al., 2016). Our findings are also consistent with recent findings in South Africa where the odds 
of HIV infection were reported to be nil for individuals who are homozygous for RHCE*CC 
(Davison et al., 2018). This prompted us to revisit a previous dataset involving 544 subjects. 
In this dataset only 6 individuals were homozygous for the C antigen and none of them were 
infected.  
CTLs are important in the control of viremia in acute HIV-1 infections (Goonetilleke et al., 
2009). They also correlate negatively with infection rates(Oxenius et al., 2004) and with good 
prognosis (Rinaldo et al., 1995). Moreover, they have been linked to slower progression of 
disease in non-progressors by producing HIV-1-specific CTL responses (Betts et al., 2001, 
Alimonti et al., 2006) and increased perforin production in HIV-infected non-progressors 
(Migueles et al., 2002).  
The enhancement of CTLs points to a mechanism involving major histocompatibility class I 
(MHC-I) response, in which a cell-mediated rather than humoral response is invoked, and this 
kind of response is critical for viral infections such as HIV. This phenomenon appears to be 
enhanced when the RHCE*C antigen is expressed on erythrocytes. Erythrocytes and 
erythrocyte-bound platelets harbor HIV virions (Beck et al., 2013). In this connection, platelets 
have been shown to engage in direct MHC-I antigen presentation to CTLs (Chapman et al., 
2012), a phenomenon that has also been documented in murine megakaryocytes (Zufferey et 
al., 2015).  The RHCE*C phenotype appears to enhance this process, possibly by engaging its 
associated CD47 as the activator of CTLs (Seiffert et al., 2001).  
Antigen presentation is normally accompanied by co-stimulatory responses that enhance clonal 
expansion of the specific CTL (Watts, 2010). We propose therefore, that the virus-platelet-
erythrocyte-T-cell interaction may explain the connection between RHCE*C and its protective 
role against HIV. Our results further suggest that the presence of C, rather than the other Rh 
antigens associated with CD47, may be responsible for the enhanced CTL response.  
CD47 is the one erythrocyte antigen most commonly associated with T-cell activation events 
(Reinhold et al., 1997, Ticchioni et al., 2001, Seiffert et al., 2001, Pettersen et al., 1999). This 
glycoprotein is widely expressed on somatic cells including erythrocytes(Ripoche et al., 2004), 
a characteristic which makes the direct interaction of HIV-bearing erythrocytes with T-cells 
and phagocytes probable. 
CD47 also interacts with its ligands on monocytes and T-lymphocytes in signal-transducing 
events. In this regard, it binds to signal regulatory protein-α (SIRPα) in a high-affinity 
interaction that results in T-cell activation(Seiffert et al., 2001). Binding of CD47 to  SIRPβ2 
enhances adhesion of T-cells to antigen-presenting cells and therefore enhances cell-mediated 
immunity(Piccio et al., 2005). In activated T cells, such as occur following HIV infection, 
CD47 promotes Fas-mediated apoptosis(Manna et al., 2005).  All these events would work to 
eliminate HIV-infected CD4+ cells and therefore minimize the chances for an infection to be 
established. 
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Evidence from empirical HIV prevalence data 
To further investigate its potential role in the epidemiology of HIV worldwide, we compared 
the frequency of the RHCE*C antigen across populations with varying degrees of HIV 
prevalence. Invariably, countries with an antigen frequency lower than 30% were consistently 
associated with highest prevalence rates in their regions. In Southern Africa, antigen frequency 
data was available only for Botswana (Motswaledi et al., 2016) and South Africa (Tax et al., 
2002). Cote d’Ivoire and Nigeria (Gwaram, 2013) likewise had the lowest antigen frequencies 
(Bogui et al., 2014) and highest HIV prevalence in West Africa (UNAIDS, 2016a). In contrast, 
other African countries with higher antigen frequencies had low HIV-prevalence rates 
comparable to or slightly above other non-African countries, such as Argentina (Cotorruelo et 
al., 2008), Brazil (Guelsin et al., 2011), Thailand (Nathalang et al., 2001), Laos 
(Keokhamphoui et al., 2012), India (Makroo et al., 2013), Netherlands (Tax et al., 2002), Iran 
(Shokouhi Shoormasti et al., 2011) and China (Ma et al., 2018), where the RHCE*C frequency 
is higher than 40%. These African countries included Mali (Ba et al., 2015), Mauritania 
(Hamed et al., 2013), Ethiopia (Tax et al., 2002), Sudan (Elfadni et al., 2014) and South 
Africans of Asian origin (Tax et al., 2002).  
Of further note and interest was the Caribbean statistics. The Caribbean Islands represent the 
second highest HIV-prevalence outside Africa (UNAIDS, 2016b). Apparently, a significant 
proportion of this population originates from Africa and the RHCE*C antigenic profile 
performed in Curacao (Tax et al., 2002) is similar to that of the African countries where high 
HIV rates are experienced. We propose that the RHCE*C antigen is important for HIV 
immunology and probably explains the genetic basis for the geographical distribution of the 
epidemic.  
Conclusion 
The results of this study indicate that high HIV rates occur only in geographical locations of 
low RHCE*C frequencies. The lack of this antigen in Botswana and countries with similar 
frequencies may have contributed to the rapid spread of HIV-1 in these populations. Results 
also suggest an immunological role of an Rh system antigen, unreported hitherto. 
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Abstract 
 
BACKGROUND: Many studies have implicated erythrocytes in HIV-1 pathogenesis and as 
viral reservoirs. We previously reported a high risk for HIV infection associated with P1 blood 
group.in Africans. P1 belongs to a group of glycolipids known to facilitate viral membrane 
fusion. The aim of this study was to investigate the possibility of HIV RNA inside P1 
erythrocytes. 
METHODS: Viral load measurements were made in 120 untreated, HIV-1 infected patients. 
Qualitative PCR (n=27) was done on purified erythrocytes to detect erythrocyte-associated HIV-
1 RNA. Results were then compared across categories of P1. 
RESULTS: Viral RNA was detected in both lysate and membranous fraction of purified 
erythrocytes, including those with undetectable plasma viral load. Plasma viral load did not 
differ between individuals positive or negative for P1. However, purified P1-positive erythrocyte 
lysate contained more viral RNA (Mann-Whitney U-test, P= 0.032). Erythrocyte-associated 
RNA was independent of plasma VL. 
CONCLUSIONS: The higher level of intra-erythrocytic RNA in P1 subjects is a novel finding 
consistent with viral fusion facilitated by glycosphingolipids, possibly accounting for the 
observed risk of infection associated with P1. The study also suggests a new viral reservoir 
hitherto undescribed. 
Key words: HIV-1 RNA; P1 blood group; viral load; glycosphingolipids, erythrocytes. 
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Introduction 
The P-blood group system is comprised to three antigens – Pk, P and P1.  The antigens are 
glycosphingolipids (GLS) built by addition of sugars to a galactosyl ceramide, the basic 
sphingolipid backbone(Hellberg, 2007). The P antigen is derived by addition of sugars to the 
Pk antigen. The P1 antigen synthesis follows a separate pathway resulting in a more complex 
structure carrying more glycosyl residues(Spitalnik and Spitalnik, 1995). In blood transfusion, 
the P1-blood may occasionally cause transfusion reactions(Spitalnik and Spitalnik, 1995), 
although most of the cases  are generally of the cold-reacting IgM class and therefore clinically 
insignificant. This blood group occurs among individuals of African descent with high 
frequency but relatively rare among Caucasians(Hellberg, 2007).  
Seemingly contradictory reports have been published regarding the role of the Pk antigen with 
respect to predisposition to HIV infection. In some reports, GLS were reported to promote HIV 
membrane fusion to susceptible CD4 cells (Hammache et al., 1999, Puri et al., 1998a). In 
particular, the Pk blood group was thought to enhance infection with X4 viruses while P 
enhanced R5 strains(Puri et al., 1998a). In other reports, lipid rafts comprising of GSL and 
cholesterol were considered to be sufficient for viral fusion without the need for co-
receptors(Yang et al., 2015, Rawat et al., 2006). 
In a contrary report, the Pk blood group was reported to be protective against HIV infection in 
vitro(Lund et al., 2009).   This perspective was further strengthened by the observation that 
patients with Fabry Disease, in which an intracellular accumulation of the Pk antigen occurred, 
were resistant to HIV infection (Lund et al., 2005, Ramkumar et al., 2009).  A possible 
explanation of this apparent contradiction was that optimal amounts of Pk are required for viral 
fusion. However, excess quantities of GSL protects the cell from infection by competing for 
the virus and thus preventing it from effectively fusing to the cell membrane(Lund et al., 2009).  
To date, no reports specifically linking the P1 antigen to the risk of HIV infection have been 
found. However, a number of other reports have demonstrated that HIV directly interacts with 
RBC, some via glycosphingolipids, and this interaction may be important in the epidemiology 
and pathogenesis of the virus (Beck et al., 2009). For example, in 2002, Hess and colleagues 
reported some HIV-1 to be associated with erythrocyte membranous ghosts in about 98% of 
HIV-1-infected patients (Hess et al., 2002). The erythrocyte-associated HIV was detectable in 
one third of the patients in whom plasma viral load was undetectable. The erythrocyte-
associated HIV in some of the patients exceeded that associated with leukocytes and was 
associated with advanced clinical stages of the disease. Subsequent reports by Fierer and 
colleagues (2007), however, strongly disputed the presence of erythrocyte-associated HIV in 
patients with long term viral suppression while acknowledging it in those who have not 
achieved  viral suppression .  
The binding of the virus to the erythrocytes has been attributed to a number of mechanisms, 
including the use of complement receptors normally used for clearance of antigen/antibody 
(immune) complexes(Horakova et al., 2004). Although some of the virus was bound to 
erythrocytes via the normal mechanisms of immune-complex clearance using complement 
receptor 1 (CR1), these investigators also noted that the virus also bound to erythrocytes via a 
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non-complement receptor pathway, suggesting that molecules other than complement may be 
operational in this association(Horakova et al., 2004). 
In 2012, Garcia and colleagues (2011) reported the presence of anti-gp160/120 antibodies on 
erythrocyte surfaces. In addition, they documented that such antibodies on the red cells were 
responsible for capturing free plasma viral particles and may account for reduction of plasma 
viral load. This followed their earlier report in which viral p24 was detected on erythrocytes 
even in patients with undetectable plasma viral load (Garcia et al., 2011).   
In addition to erythrocytes, P1 antigen is also expressed on lymphocytes (Pourazar, 2007) and 
therefore presents a theoretical possibility of heightened risk of HIV-infection for subjects 
expressing the P1 antigen.  
In the current study, we investigated the possibility of the virus being present inside 
erythrocytes solely on the basis of the fusogenic property of the P1GSL. . If found inside the 
erythrocytes, we also sought to find out if this was dependent on plasma viral load.  
Methods 
The study enrolled120 residual blood samples from HIV-1-infected individuals, (48 males and 
72 females) prior to initiation of highly active anti-retroviral therapy at Julia Molefe Clinic in 
Gaborone, between May and June 2016.  
. The study was approved by the University of Botswana’s Office of Research and 
Development, Human Research and Development Committee of the Ministry of Health and 
Wellness, Gaborone District Health Management Team and the Research Ethics Committee, 
of the faculty of health and Wellness Sciences, Cape Peninsula University of Technology 
(Appendix A-D). Individual consent was not needed since the study used anonymized, residual 
samples(ISO, 2007). 
The viral load was determined by use of the Cobas® Taqman 48 analyser (Pleasanton, CA., 
USA), while the RNA qualitative test for HIV-1 was performed using the COBAS® 
Ampliprep/COBAS® Taqman HIV-1 qualitative test, version 2.0 (Pleasanton, CA., USA). The 
samples were further phenotyped for using anti-P1 antibody (Fortress Diagnostics, Antrim, 
UK) according to the manufacturer’s instructions. The reactivity of the antiserum was 
confirmed by use of P1-positive and P1-negative erythrocytes selected from an antibody 
identification panel, Bio-Rad DiaPanel®, Lot 45241.88.1, (Cressier FR, Switzerland). CD4, 
CD3, CD8 and CD45 counts were enumerated using the FacsCalibur ® flow cytometer 
(Becton-Dickinson, San Jose, CA. USA). 
Viral RNA detection was performed on purified erythrocytes. To achieve this, 1 ml of the 
packed red cells was diluted with an equal volume of normal saline and then overlaid on 14ml 
of ficoll, followed by centrifugation at 400xG for 30 minutes. The suspended leukocyte layer 
was removed by aspiration together with all the saline and ficoll above the erythrocytes. The 
remaining cells were again diluted in 1 ml normal saline and subjected to a second round of 
ficoll gradient centrifugation. The cells were then washed three times with 14 ml of normal 
saline. The supernatant of the last wash was tested for viral RNA or DNA using the COBAS® 
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AmpliPrep/COBAS® Taqman® (Pleasanton, CA., USA) and none was detectable, indicating 
a successful removal of unbound viral nucleic acids.  
A sample was reconstituted for CD45 testing by adding equal volumes of the purified packed 
red cells and normal saline to bring the haematocrit to 41.3±1.8%. The CD45 determination 
was repeated to assess white cell depletion and a reduction of more than 97% after the first and 
over 99% after the second purification was achieved.  
Subsequently, the purified cells were lysed with 1 ml of distilled water and allowed to lyse on 
a rotary mixer for 5 minutes before being centrifuged at 1000xG for 3 minutes to pellet 
erythrocytic ghosts and any virus that might have been attached to them. The top 500µL of the 
RBC lysate was removed and tested for viral nucleic acids as described above, to demonstrate 
the presence, if any, of intra-erythrocytic viral RNA in the lysate. 
The remainder of the sample was mixed by vortexing and viral RNA was also determined, 
which would represent the membrane-bound RNA plus that from the residual hemolysate. The 
number of PCR cycles taken to show a positive reaction in the membranous fraction or lysate 
was used as a proxy for viral concentrations in the two fractions against an internal standard. 
The median difference in cycles to reach a positive reaction were compared according to P1-
carriage for statistical significance (number of cycles for lysate minus the number of cycles for 
stroma). For the purposes of comparison in this study, a high viral load in HIV-infected patients 
was defined as any value above Log10VL=4.97, the viral set-point previously determined for 
this population. The results were analysed using the IBM SPSS version 24 statistical software.  
Results 
The viral load and lymphocyte populations did not differ between individuals positive or 
negative for P1. However, the median number of additional cycles required to reach a positive 
reaction for erythrocyte lysate-associated viral RNA was smaller for P1-positive individuals 
than for the P1-negative (Mann-Whitney U-Rank-Sum test, P=0.032), indicating a higher 
intracellular content of viral RNA in P1-positive erythrocytes. The data is presented in Table 
6.1. 
Table 6. 1 - Comparison of RNA-PCR results in untreated HIV-1-infected patients.  
Blood Group (n=10) No of PCR Cycles 
 Median  IQR 
P1-positive 0.9 0.3 
P1-negative 4.5 3 
P-value 0.032  
 
Erythrocyte-associated RNA (E-RNA) was estimated in 27 patients and was detectable in 22 
(81%) and undetectable in 5. Of these 5, only one had undetectable plasma viral load (pVL).  
On the other hand, E-RNA was demonstrable in 6 patients who had undetectable pVL. Of the 
22 with demonstrable E-RNA, 10/22 (45%) demonstrated the virus on both the stroma and 
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lysate. Most of the E-RNA was associated with the stroma than the lysate. Only one sample 
yielded more RNA from the lysate than the stroma.  
 
We also compared the prevalence of HIV across countries for which P1 frequencies were 
known. The results are shown in Table 6.2 
 
Table 6.2: Comparison of P1 frequency with HIV prevalence in various countries showing 
that high P1 frequency is associated with high HIV prevalence 
Country P1 frequency (%) HIV Prevalence (%)  
Botswana 74.6 21.9  
Uganda 89 6.5  
Laos 18.97 0.3  
Turkey 0.5 *  
Malaysia 40 0.4  
Thailand 30 1.1  
*Data for Turkey not available, but official reports suggest low prevalence (Ay and Karabey, 
2006) 
Discussion 
The presence of HIV virions on erythrocytes and erythrocyte-bound platelets has been 
documented by various reports (Beck et al., 2013, Hess et al., 2002, Garcia et al., 2011). 
However, some investigators have refuted the presence of erythrocyte-bound HIV in virally 
suppressed patients(Fierer et al., 2007). The current study confirms the presence of viral RNA 
from purified erythrocytes in patients with undetectable plasma viral load. The detection of 
intra-erythrocytic viral RNA is another novel finding hitherto unreported.  
Although the P1 positive and P1-negative groups did not differ with respect to plasma viral load, 
the PCR analysis of the erythrocyte lysate revealed the presence of more intra-erythrocytic 
viral RNA in P1-positive than negative samples. This observation is consistent with the role of 
glycosphingolipids in enhancing viral fusion (Hammache et al., 1999, Puri et al., 2004, Puri et 
al., 1998b, Puri et al., 1998a) and probably explains the increased risk of HIV infection 
observed in P1-positive individuals (Motswaledi et al., 2016).  P1 has a wide tissue distribution 
(Hellberg et al., 2013), including its expression on HIV-susceptible cells such as monocytes 
and lymphocytes (Dunstan, 1986, Pourazar, 2007). Our results corroborate the findings of 
Yang et al. (2015) who reported that lipid rafts, which are rich in sphingolipids are “necessary 
and sufficient for membrane targeting and fusion” in human immunodeficiency virus infection  
Erythrocyte-associated HIV (E-RNA) was demonstrable in the majority of patients with or 
without detectable plasma viral load (pVL), consistent with other reports (Beck et al., 2009, 
Hess et al., 2002, Garcia et al., 2012, Garcia et al., 2011). However, E-RNA could not be 
demonstrated in some samples with detectable or even high pVL, suggesting that the 
association of the virus with erythrocytes is not simply a function of plasma viral load. The 
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detection of viral RNA in erythrocyte lysate suggests alternative pathways for viral entry into 
cells independent of CD4+ as suggested by other investigators (Garcia et al., 2012). However, 
this analysis was limited by the relatively small sample size for intra-erythrocytic viral RNA.  
Our results suggest that the risk of infection associated with P1 potentially emanates from its 
ability to promote viral fusion. Furthermore, the presence of viral RNA in erythrocyte lysate 
suggests an additional viral reservoir that may need to be addressed for successful eradication 
of HIV infection. This blood group has a high frequency among individuals of African descent 
and may have contributed to the high infection rates in this population. 
We also looked at HIV prevalence among countries for which P1 frequencies were known. 
Although data was only available from five countries, the only country with a high prevalence 
rate was also the only country with a high P1 frequency. The presence of P1 can therefore not 
be excluded as a contributing factor to HIV prevalence in those countries. 
Conclusion 
We report for the first time, the occurrence of HIV RNA in the lysate of erythrocytes. This 
phenomenon is independent of plasma viral load and potentially explains a GSL-based, 
receptor-independent entry of the virus into those cells possessing adequate levels of membrane 
GSL. Furthermore, The low frequency of P1 in countries with low HIV prevalence might 
corroborate our findings that P1 carriage increases vulnerability to HIV infection. 
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CHAPTER 7 
GENERAL DISCUSSION AND CONCLUSION 
 
 
Aims and Objectives 
The aim of this project was to study the relationship between blood groups and HIV-infection. 
HIV infection in Botswana has not been linked to particular blood groups. In fact, the 
distribution of blood groups other than ABO in Botswana is not known. Furthermore, very few 
studies elsewhere have addressed this matter and the few that have been done only looked at 
ABO and Rh(D) blood groups.  This is hitherto the most exhaustive study of the role of various 
blood groups in HIV pathology and epidemiology. The study therefore aimed to: 
1. Determine the frequencies of blood groups in the Botswana population with respect to 
the following antigens among uninfected controls and HIV-infected individuals: A, B, 
“O”, D, C, c, E, e, Fya, Fyb, Jka, Jkb, Kpa, Kpb, Lea, Leb, Lua, Lub, M, N, P1, S, and s. 
2. Compare the occurrence of blood groups in HIV-infected versus uninfected individuals. 
3. Determine, where possible, the underlying mechanisms. 
The frequency of the selected blood groups in Botswana were determined and found to be 
compatible with documented frequencies for Africans in general. The occurrence of HIV 
infection in these blood groups was also compared and the antigens Rh2, Lub and P1 were found 
to be associated with infection as detailed below.  
ABO Blood Groups 
Many studies have reported a relationship between the risk of HIV-infection and some blood 
groups (Abdulazeez et al., 2008, Anstee, 2010, Branch, 2010, Neil et al., 2003). In one study, 
naturally-occurring ABO antibodies were reported to neutralize HIV from lymphocytes of 
group A blood donors (Arendrup et al., 1991). According to this report, it would be expected 
that ABO antibodies should offer some level of protection against HIV across ABO blood 
groups (Neil et al., 2003, Neil et al., 2005).  However, there is no consensus on the role of ABO 
blood groups with respect to the risk of HIV infection (Nneli et al., 2004, Abdulazeez et al., 
2008).  
We compared the prevalence of 23 blood group antigens in HIV-infected and uninfected 
individuals in Botswana. Our study did not find any relationship between risk of HIV-infection 
and any ABO blood group. In particular, none was found for blood group O, which produces 
both anti-A and anti-B, and should be expected to be least susceptible to HIV-infection if these 
conferred any level of protection. It is noted, however, that blood group O is the most prevalent 
among the subjects of the current study, and therefore infections between group O individuals 
would not be affected by presence of naturally occurring anti-A or anti-B. Reports concerning 
susceptibility of ABO blood groups to HIV infection therefore vary extensively. Considering 
the inadequate statistical analysis employed in some of the studies that reported such a 
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relationship (Ukaejiofo and Nubila, 2006, Sayal et al., 1996, Nneli et al., 2004), it is probably 
safe to conclude that no data exists to support the role of ABO blood groups in affecting the 
outcome of HIV exposure. 
Blood Group C (rh’, Rh2 or RHCE*C) 
Of all the antigens studied, the blood groups C (Rh2) and E (Rh3) in the Rh system were 
associated with a reduced risk. However, with rigorous statistical analysis, the carriage of blood 
group E did not sustain significance as a protective surface molecule. We attributed this initial 
significance to its simultaneous co-expression and co-localization with C (Ripoche et al., 
2004). Blood group C was associated with a 40% risk reduction for HIV infection.  The 
association of this blood group to potentially-enhanced cellular cytotoxicity is a novel finding 
in this current study which has not been reported elsewhere in the literature. Other than its 
association to urea transporter proteins, the function of group C antigens is unknown. We 
provide here a potential immune functional role of an antigen in the Rh blood group system. 
Further analysis revealed that the frequency of a high absolute CD8 count among HIV-infected 
patients was higher among C-positive subjects, indicating a heightened cell-mediated 
cytotoxicity. This is the major mode by which the immune system deals with cells that present 
non-self-antigens such as virally-infected or cancer cells (Gulzar and Copeland, 2004, 
Migueles et al., 2002). The evidence gleaned from this study suggests that the protective effect 
of blood group C emanates from its ability to eliminate the infection via cell-mediated 
immunity.  
This immune function, hitherto unreported, is likely associated with CD47, a glycoprotein that 
is spatially associated with Rh antigens on the erythrocyte membrane (Dahl et al., 2003) and 
functions to enhance antigen presentation (Piccio et al., 2005) and cytotoxicity (Seiffert et al., 
2001, Ticchioni et al., 2001). It is likely that the C-antigen accelerates the effectiveness of 
CD47, since other Rh antigens that are known to be spatially associated with CD47 (E, e, c, 
Duffy) did not show any evidence to suggest a protective role. 
It is noted, however, that Rh antigens are expressed primarily on erythrocytes (Anstee and 
Tanner, 1993), and that erythrocytes are not considered immunologically active cells. This 
notwithstanding, it is an established fact that erythrocytes bind HIV by various means (Beck et 
al., 2013, Garcia et al., 2012, Hess et al., 2002, Horakova et al., 2004). HIV also binds to other 
cellular components such as platelets (Beck et al., 2013), and these antigens are presented to 
cytotoxic T-cells via MHC class I restriction (Chapman et al., 2012, Zufferey et al., 2015) to 
provoke a cell-mediated immune response. Erythrocytes and platelets are the most numerous 
blood cells. The amount of HIV bound to these components by various mechanisms is not only 
substantial, but erythrocytes preferentially capture the infectious virions (Beck et al., 2009, 
Beck et al., 2013) and present these via MHC class I restriction (Chapman et al., 2012, Zufferey 
et al., 2015). Dendritic cells also present exogenous viral antigens by a special cytotoxic MHC-
I pathway (Buseyne et al., 2001, Moris et al., 2004). However, since Rh antigens are not 
expressed on leukocytes, the anti-viral mode associated with Rh(C) is more attributable to 
erythrocyte associated virions, where they are captured and concentrated on the erythrocyte 
membrane (Beck et al., 2009). Moreover, since erythrocytes bind the most infective form of 
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the virus (Beck et al., 2013, Beck et al., 2009), and then subject it to cell-mediated cytotoxicity 
(Alter et al., 2002, Buseyne et al., 2001), it is plausible that a blood group that facilitates cell-
mediated immunity would prevent establishment of an infection.  
During blood grouping with anti-C, the strongest agglutination reactions (4+) were more 
common among uninfected than infected individuals. Since Rh antibodies react stronger with 
homozygous cells, which have higher antigen density than heterozygous ones, we further 
examined the data for homozygous carriage of Rh(C). Here, only six individuals out of 409 
were homozygous for the C antigen. Interestingly, none of these six were infected with HIV.  
It would be interesting in a large sample study to see if individuals who are homozygous for 
blood Rh2 ever get infected with HIV. A recent study in South Africa reported a zero 
probability for infection in homozygous C individuals (Davison et al., 2018). Particularly 
interesting would be the Rh2 profile of non-progressors and elite controllers. Our data suggests 
that they would be mostly Rh2-positive and more likely to be homozygous for the antigen. 
This observation suggests that the protection is related to the density of antigens on the 
erythrocytes. From a population genetics perspective, this is a blood group with a low 
frequency among individuals of African origin (27%), compared to Northern Indians (85%) or 
Caucasians (68%). These findings are important from an epidemiological perspective as the 
rarity of Rh2 among Africans may have contributed to the severity of the epidemic in the 
continent (Motswaledi et al., 2016). In fact a close examination of the world statistics 
demonstrates that HIV infections are high only in those regions of the world where Rh(C) 
frequency is low (Table 7.1). 
 
Duffy Blood Group 
Another blood group system implicated in HIV-infection is the Duffy blood group system. A 
fierce debate has previously raged between investigators whose data suggested an increased 
risk (Lachgar et al., 1998, He et al., 2008) while others suggested a protective role (Ramsuran 
et al., 2011) and others argued for no effect at all (Winkler et al., 2009).    Our study did not 
find any relationship of the Duffy antigens to the risk of HIV infection. However, we note that 
the Duffy antigen co-localizes on the erythrocyte membrane with the C antigen (Ripoche et al., 
2004, Anstee and Tanner, 1993), which was found to be protective in this study (Motswaledi 
et al., 2016).   
Lutheran Blood Group 
The Lutheran antigens are also known as basal cell adhesion molecules (BCAM) (Chang et al., 
2017). Lub, but not Lua, was associated with a three-fold risk for HIV-infection (Motswaledi et 
al., 2016). This antigen has wide tissue distribution and is present on monocytes, erythrocytes 
and endothelial cells (Parsons et al., 1995). It is a natural ligand for laminin, an intercellular 
matrix protein that has been implicated in vascular occlusion occasioned by adhesion of sickled 
erythrocytes to vascular endothelia. The role of adhesion molecules in cardiovascular disease 
is an active area of research (Østerud and Bjørklid, 2003, Lafrenie et al., 1996, Pedraza et al., 
2000, Weerasinghe et al., 1998). Monocytes not only adhere to laminin, but also migrate on it 
into the tissues (Pedraza et al., 2000). For this reason, Lutheran blood groups are an important 
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consideration in cardiovascular disease. The most significant finding in this study was a lower 
absolute monocyte count in individuals positive for Lub antigen.  
The correlation between total cholesterol and phagocytic cells was also studied. As reported by 
others, cholesterol levels correlated negatively with phagocytes (Solomkin et al., 2007, 
Frostegard et al., 1990). This cholesterol-related phagocyte depletion was present only in HIV 
infection and probably reflects the other aspect of atherosclerosis – inflammation, resulting 
from chronic HIV infection. Considering that atherogenesis requires both macrophages 
(transformed monocytes), cholesterol and inflammation, we observe here a combination of 
these factors in a fashion that logically favours atherogenesis. Moreover, we note that this 
interaction is enhanced in Lub-positive subjects but absent in Lub-negatives. This evidence 
strongly suggests that Lu/BCAM likely plays a role in endothelial retention of monocytes that 
leads to atherogenesis, and that such adhesion may be a function of non-HDL cholesterol. 
Moreover, since HIV-infected monocytes have enhanced epithelial transmigration, it is 
probable that the presence of the Lu/BCAM adhesion molecule enhances this process and 
results in the introduction of the virus to anatomical sites such as the lymph nodes, where HIV-
susceptible cells are concentrated. This would explain the observed, increased risk associated 
with this blood group. 
Since the negative correlation between cholesterol and phagocyte counts was not observed in 
uninfected individuals, we conclude that HIV or its effects, especially its inflammatory effects, 
are responsible for promoting leukocyte depletion in the presence of cholesterol. This, if 
confirmed by further investigations, could explain the increased risk of cardiovascular diseases 
in HIV infected patients.  
The P1 Blood Group. 
A novel finding regarding the P1 blood group in this study was its association with risk of HIV 
infection and the presence of HIV RNA in the lysate of P1 erythrocytes. The P1 blood group is 
comprised of glycosphingolipids, which are known to facilitate viral fusion independent of co-
receptor expression (Hammache et al., 1999) or enhance cofactor efficiency (Puri et al., 1998).  
The current study corroborated the risk associated with the glycosphingolipid P1. This blood 
group was associated with a two-fold odds ratio for HIV infection. Moreover, the study 
confirmed association of the virus with erythrocytes even in those patients with undetectable 
plasma viral load. The erythrocyte-associated virus appears to be independent of the viral load 
as it was detectable in those with undetectable plasma viral load and absent in some with high 
viral load. The detection of viral RNA in the lysate of erythrocytes suggests presence of the 
virus inside the erythrocytes, which was another novel finding of the study.  
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Combination of risk of HIV-1 Infection based on the ratio of the risk to protective blood 
group. 
Table 7.1 presents frequencies of the protective RHCE*C and the risky P1. In Africa, P1 
frequencies were only available for Uganda and Botswana. The ratio of the frequencies of the 
risky over the protective blood groups indicates Uganda as the most HIV-risk-prone population 
followed by Botswana. For comparison sake, the frequency ratio for China is used as the 
denominator. The least vulnerable, according to this model would be Turkey, Laos, Malaysia 
and China. Other countries have a ratio less than one, indicating a protective advantage. The 
Lub blood group was excluded from this analysis since it occurs in high frequency across most 
ethnic groups (Karamatic et al., 2003).  
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Table 7.1: Comparison of the risk of HIV-1 Infection based on the ratio of the risk to 
protective blood group. 
Country/Community RHCE*C 
Frequency 
P1 
Frequency 
P1/RHCE*C 
ratio 
Risk 
Factor 
based 
on 
China 
HIV 
Prevalence 
Botswana 29.70 74.6 2.51 5.8 21.90 
Uganda 3.62 89 24.59 57 6.5* 
China 88.1 37.82 0.43 1 0.04 
Laos 60.30 18.97 0.31 0.72 0.30 
Malaysia 96 40 0.42 1 0.4 
Northern India 82.02 71.92 0.88 2.0 0.26 
Thailand 51.50 30 0.58 1.3 1.10 
Turkey 43 0.5 0.01 0.02 ** 
*1994 prevalence data = 24.8% (Kilian et al., 1999) 
**Official statistics not available, but HIV not considered a threat(Ay and Karabey, 
2006).  
 
Conclusion 
Taking all data into account, human blood groups, especially Lub, and P1, were observed to 
increase susceptibility to HIV infection with data consistent with their known biochemical 
properties. Particularly novel in this study is the finding of viral RNA in erythrocyte lysate 
since HIV has not been reported to enter erythrocytes. Moreover, Rh(C) was found to be 
protective against HIV and was for the first time linked to an immunological function, 
particularly involving CD8+ lymphocytes. Our data also shows that a combination of the risky 
blood groups and the protective activity may influence the severity of the HIV epidemic in a 
region, especially exemplified by analysis of reports on the prevalence of HIV and the 
distribution of the blood groups in Africa and other parts of the world. This, to our knowledge 
is the first comprehensive documentation of the role of blood group systems in HIV 
immunology.  
The study was limited in that while it documented the association of RH2 with cell-mediated 
immunity, no specific CD functions were investigated. Future experiments will need to include 
cytotoxicity studies that include measurement of granzyme and interferon. 
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CHAPTER 8 
RECOMMENDATIONS 
 
Blood Group C 
1. This blood group was protective and showed an increased proportion of cytotoxic T 
cells. Moreover, the frequency of this antigen was consistently low in countries with 
high HIV rates of infection. However, HIV-specific CD8 T-cell responses were not 
measured in this study to confirm enhanced cytotoxicity. A study is hereby 
recommended to investigate HIV-1-specific T cell responses such as Interferon gamma 
response to stimulation with HIV-specific peptides. This would confirm the functional 
role of the Rh2 antigen in the immunological response to HIV. 
2. Most countries in Africa do not have data relating to these antigens that relate to HIV 
susceptibility. A multi-national study is needed to corroborate our findings, similar to 
the South African study cited in this document. 
3. Another pertinent study would be to determine the RhC frequency among HIV-infected 
non-progressors and elite controllers. 
4. Other profitable studies could investigate how erythrocyte-bound virions are presented 
to T-cells and the role, if any, of CD47 in enhancing the presentation of such antigens. 
5. The use of homozygous Rh2 hematopoietic stem cells may benefit those who are Rh2 
homozygotes. These would not reject the Rh2 cells but would increase the antigen 
expression and consequent resistance to HIV. Moreover, a more permanent vaccine 
may be possible by introducing hematopoietic stem cells to developing foetuses who 
are likely to take adopt the immune hematopoietic cells and acquire HIV-resistance. 
Lutheran Blood group (Lu/BCAM, LU2 or Lub) 
1. The results concerning this blood group showed that the Lutheran blood group, in the 
presence of high cholesterol levels, promotes depletion of circulating monocytes. This 
phenomenon constitutes an atherogenic environment. Recommended studies include 
the use of a larger sample size to study the relationship between high lipids, 
inflammation, LU2 antigen carriage, and carotid intima/medial thickness. This could 
help in establishing the genetic link of the Lutheran blood group to cardiovascular 
disease in HIV-infected individuals.  
2. Other studies could also focus on the effect of the blood group on monocyte tethering, 
migration, as well as the combined atherogenic effect of HIV infection and Lub.  
3. Furthermore, measures of monocyte activation such as soluble CD163 (sCD163) could 
be used to study monocyte activation between Lub-positive and negative individuals. 
P1 Blood Group 
1. The P1 blood group was associated with a high risk for HIV infection. This was 
attributed to its ability to facilitate viral fusion to erythrocytes. However, this study used 
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only a small sample size to demonstrate viral RNA in erythrocytes.  Large scale studies 
are needed to explore the in vitro fusogenic effect of the blood group.  
2. If corroborated by such studies, the findings would pave the way for further studies to 
determine if such intra-erythrocytic RNA has potential to infect splenic macrophages 
when they phagocytose senescent erythrocytes, which could eventually lead to the 
development of strategies for dealing with this viral reservoir. In particular, the results 
hold promise for using RNase-laden glycosphingolipid liposomes to capture and lyse 
circulating virions as a way to effect a rapid drop in the viral load. 
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